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Infection by oncogenic human papillomavirus (HPV) is the primary cause of cervical cancer, 
where low-and middle-income countries (LMIC) have the highest incidence. Prophylactic HPV 
vaccines exist but LMIC have limited access. Therefore, alternative preventative measures against 
HPV infection and cervical cancer progression are needed. Two human proteins have been 
identified in our laboratory that modulate HPV16 pseudovirus (HPV16-PsVs) infection in vitro, 
namely surfactant protein A (SP-A) and recombinant human vimentin (rhVim).  
Previous work suggested SP-A mediated immune recognition of HPV since SP-A-coated HPV16-
PsVs enhanced viral uptake by RAW264.7 murine macrophages. These initial observations were 
confirmed using a murine C57BL/6 cervicovaginal challenge model: pre-incubation of HPV16-
PsVs with purified human SP-A significantly reduced the level of HPV16-PsV infection in vivo. 
Moreover, when isolated cells from female reproductive tracts of naïve C57BL/6 mice were 
incubated with HPV16-PsVs and stained for selected innate immune cell populations by flow 
cytometry, significant increases in viral uptake by eosinophils, neutrophils, monocytes and 
macrophages were observed over time using SP-A-pre-coated virions compared to control 
particles. 
Compared to SP-A mediated modulation of HPV infection through activation of innate immune 
responses, rhVim was suggested to directly interfere with HPV entry into host cells. Indeed, 
supplementation with non-filamentous rhVim resulted in decreased viral uptake by NIKS cells 
which was confirmed in vivo using the murine C57BL/6 cervicovaginal HPV16-PsVs challenge 
model. Co-localisation analysis employing confocal imaging, revealed that rhVim-coated HPV16-
PsVs co-localised, to a lesser degree, with surface-expressed heparan sulphate proteoglycans 
(HSPGs) than control particles. Removal of surface HSPGs on NIKS cells decreased HPV16-PsVs 
cell surface binding and internalisation, while pre-incubation of HPV16-PsVs with rhVim 
decreased viral particle binding and internalisation to a greater extent. This indicates that rhVim 
may modulate HPV16 infection by interfering with its attachment to HSPGs as well as viral 




In summary, both SP-A and vimentin modulate HPV16-PsVs infection by different mechanisms. 
These in vivo studies strongly confirm previous in vitro observations, rendering both proteins 
potentially suitable for further development into possible candidates for use in topical 





1.1 Human papillomavirus and cervical cancer 
Papillomaviruses (PVs) belong to the highly diverse family of Papillomaviridae (1). There are over 
100 characterised types of human papillomaviruses (HPVs), which have been classified as either 
low-risk or high-risk, depending on their ability to cause malignancy (1). HPVs are highly prevalent 
and are contracted through sexual activity, thus leading to significant disease burden globally. 
Infection with high-risk (oncogenic) HPVs are associated with 5% of all human cancers, and are 
the etiological agents for the development of virtually all cases of cervical cancers (2, 3). More 
than 20 oncogenic HPV types have been characterised, of which HPV types 16 and 18 are the 
most common oncogenic types globally and are the major causes of cervical cancer. These two 
high-risk HPV types contribute to 70% of all documented cases (2, 4).  
Although HPV infection is necessary, it is not sufficient for cancer development. Many co-factors 
have been established for the initiation and progression of cervical cancer, some of which 
include: long-term use of contraceptives, tobacco smoking, chronic inflammation, and co-
infection with human immunodeficiency virus (HIV) (4–6). Likely co-factors include co-infection 
with Chlamydia trachomatis (C. trachomatis) and herpes simplex virus type-2 (HSV-2), as well as 
genetic and immunological factors (5, 8–11). 
Cervical cancer is more prevalent in low-and middle-income countries (LMIC). Globally, cervical 
cancer ranks fourth for both incidence and mortality in women (12). However, it is the second 
most common cancer in South Africa (8, 12) as well as the leading cause of female cancer-
associated deaths in Sub-Saharan Africa (13). The higher incidence rate in LMIC has been 
attributed to the HIV/acquired immunodeficiency syndrome (AIDS) epidemic in Southern Africa 
(see section 1.1.3) (14).  
As infection with oncogenic HPVs is almost always the cause of cervical cancer, it has the potential 
to be preventable. Highly efficient vaccines targeting the most common oncogenic HPV types are 
on the market, but access to these vaccines by the target groups in LMIC has proven challenging 
for a number of reasons (see section 1.1.4). Therefore, alternative means to protect against 




1.1.1 HPV genome and structure 
HPVs are small non-enveloped DNA viruses. They are characterised by their circular double-
stranded DNA genomes, which are approximately 8 kilobases (kb) in length. The HPV genome is 
broken down into “early” and “late” genes (Figure 1.1A). E1 and E2 have been implicated in 
replication and transcription (15). E1 has ATPase, DNA helicase as well as origin of replication 
(ori)-specific DNA binding and unwinding activities (16). Contrarily, E2 acts as a transcriptional 
activator protein (16). It has been shown that E1 complexes with E2 for enhanced binding of the 
ori (15, 16). E4 has roles in successful genome amplification and virus synthesis, as well as a role 
in viral particle release (17). 
The function of E5 is not well described, and controversy exists about its role in the HPV life cycle. 
A study has elucidated a role for E5 in immune evasion, showing that E5 selectively 
downregulates surface human leukocyte antigen (HLA)  class I molecules (18). 
E6 and E7 are proteins with oncogenic properties, where both have been implicated in neoplastic 
transformation of cells (19). E6 specifically binds to p53, a tumour suppressor protein involved in 
controlling the cell cycle, DNA repair and apoptosis (19). Suppression of p53 by E6 results in 
dysregulation of the cell cycle, promotes cell proliferation and increases the frequency of 
spontaneous mutations, all of which are hallmarks of malignancy (19, 20). E7 binds to the 
retinoblastoma protein (Rb), another major tumour suppressor (19, 21). E7 binding to Rb releases 
the E2F transcription factor from Rb complexes, which results in the activation of genes that 
control cell proliferation (19, 20, 22). Furthermore, both E6 and E7 also play a role in immune 
evasion (detailed in section 1.1.3). 
The late proteins L1 and L2 encode for the major and minor capsid proteins, respectively. L1 
spontaneously assembles into pentameric capsomeres and comprise the majority of the 
icosahedral viral capsid (23, 24). L2 remains hidden and embedded in the pentamers and 







Figure 1.1: Schematic representation of the HPV genome and viral particle structure. [A] Depicted is the 
arrangement of the early E (non-structural) genes, the capsid genes (L1 and L2) and the upstream regulatory region 
(URR). Genome size as well as the position of the genes are marked in base pairs (bp). [B] Depicted is the structure 
of the HPV particle. Figure adapted from (25). 
 
1.1.2 HPV infectious cycle and malignant transformation 
HPV displays a rather specific target cell tropism and primarily infects basal keratinocytes of 
squamous epithelium, such as is found in the mucosal epithelial lining of the cervix (23, 26). It is 
well established that epithelial wounding (or damage) is a pre-requisite for efficient HPV infection 
in an in vivo setting (27–29). It is likely that abrasions in the outermost protective layers help the 
virions gain access to the mitotically-competent basal epithelial cells in the inner layers of the 
epithelium, as these are the cells that are able to establish episomal viral genome replication (26, 




shown to be involved in the initial binding and entry steps into the target cells of the basal 
epithelium. However, the exact mechanisms and surface receptors used by HPV for successful 
entry and subsequent establishment of infection remain unknown. 
What is known is that the initial cell surface molecules that HPV interact with are heparan 
sulphate proteoglycans (HSPGs) (27, 30, 31). It has also been proposed that HPV binds in a 
transient manner to laminin 332 (a protein secreted into the extracellular matrix by migrating 
keratinocytes), which results in uptake by proliferating keratinocytes expressing α6 integrin (32). 
Many infectious pathogens and viruses interact with HSPGs on the cell surface, or on the 
basement membrane, for attachment and subsequent cellular entry (33). Specifically, the L1 
capsid protein of HPV binds to the glycosaminoglycan (GAG) chains of HSPGs (27). This binding 
induces conformational changes in the capsid and facilitates proteolytic cleavage of L1 by the 
secreted serine-protease kallikrein-8 (KLK8) (27, 34). This cleavage allows for interactions 
between the capsid and cyclophilin B, which results in further conformational changes that 
exposes the L2 N-terminus containing a conserved consensus cleavage site for the host 
extracellular proprotein convertase furin (35, 36). This interaction has been shown to be essential 
for successful infection of HPV, as furin cleavage results in the exposure of a binding site on L1, 
postulated to be recognised by an unknown receptor, or receptor complex (27, 33, 34, 37). The 
described changes in virion conformation further facilitate the reduction in the binding affinity 
to HSPGs, thereby facilitating the engagement with the unknown receptor(s), or receptor 
complex (38). 
The mechanisms and pathways used by HPV for intracellular trafficking remains elusive, however, 
most studies indicate a clathrin-mediated endocytosis pathway for most HPV types, including 
HPV16 (39). This involves the localisation of HPV into early endosomes within 4 hours of cellular 
internalisation, followed by uncoating of the viral particle within the late endosome (12 hours 
after internalisation). Most studies suggest the release of a L2/viral DNA complex from the late 
endosome, followed by nuclear trafficking of this complex and subsequent viral DNA replication 
and gene expression (39). Furin cleavage has also been in implicated in successful endosomal 
escape prior to transport of the L2/viral DNA complex to the nucleus, emphasising the necessity 




The HPV life cycle is closely linked to the differentiation program of the host keratinocyte (20). 
Low levels of viral DNA are made in infected mitotically active keratinocytes within the basal 
epithelial layer (approximately 100 genomes per cell), where expression of the E1 and E2 proteins 
help maintain this low level of replication, as well as the subsequent separation of the viral DNA 
into the dividing cells (5, 20). The infected daughter cells leave the mitotic phase and migrate to 
the upper epithelial layers (spinous layer), where they enter the differentiation phase (25). This 
results in upregulation of viral E6 and E7 protein expression, which disrupts the normal cell cycle 
control and drives these differentiating cells into the S phase. This disruption allows for viral DNA 
replication, amplifying the copy number to thousands per cell, as well as the expression of the 
late viral L1 and L2 capsid proteins (25, 41). The capsid proteins spontaneously assemble to 
encapsidate the viral genome, where the newly formed virions are released from the outermost 
layer of the epithelium (the cornified layer, Figure 1.2) (25). The time from infection to viral 
release is relatively slow and takes approximately three weeks (26) .  
For malignancy to occur, the viral genome must integrate into the host keratinocyte genome (5, 
19). Integration from the perspective of HPV is “accidental” as it results in a dead-end for virus 
production (42). However, viral genome integration into the host genome results in a constant 
level of E6 and E7 expression (5). Integration disrupts the expression of E4, E5, and E2, the latter 
of which controls expression of the E6 and E7 proteins (19). Overexpression of E6 and E7 genes 
results in overproduction of the E6 and E7 oncoproteins (19), consequently leading to the 
repression of the tumour suppressor proteins, p53 and Rb (see section 1.1.1). This results in 





Figure 1.2: Life cycle organisation of HPV upon infection of basal keratinocytes. Diagrammatic representation of 
the skin (layers indicated on the left) to reveal the pattern of HPV gene expression and viral DNA copy number 
(indicated on the right), upon HPV infection resulting from an abrasion that exposes the basal epithelial layer. Figure 
adapted from (43). 
 
1.1.3 Immune evasion strategies of HPV 
HPV employs several mechanisms to effectively evade the innate immune responses. As stated 
previously, the infectious life cycle of HPV is closely linked to the differentiation of the host 
keratinocyte (20, 25). There is no cytolysis as a result of low viral replication throughout most of 
the viral life cycle, where viral release only occurs after the basal keratinocyte has migrated to 
the outer epithelial layers and has fully differentiated. Viral particles are therefore only released 
where immune surveillance is minimal, thus making antigen presenting cells (APCs) ineffective 
(25).  
Under normal conditions, keratinocytes can either constitutively or be induced to secrete a range 
of pro-inflammatory cytokines, including interleukin (IL)-1, -6, -10, and -8. IL-1 in particularly plays 
a vital role in activation of APCs such as Langerhans cells (LCs) and macrophages, which in turn 
present antigens to T-helper cells (25, 44). As low levels of viral protein are produced at the early 




replication, little to no pro-inflammatory cytokines are released by infected keratinocytes. As a 
result, no immune response is elicited as the APCs - dendritic cells (DCs) and macrophages - are 
ineffective in non-inflammatory environments (25). Throughout its life cycle, HPV remains within 
the epithelium and does not have a viraemic or blood-borne phase, resulting in minimal exposure 
to host immune defences (25). Evidence has shown that HPV, from the start of the infectious 
cycle, dampens keratinocyte cytokine responses (25).  
Like many other DNA viruses, HPV has evolved mechanisms for inhibiting the synthesis and 
release of the cytokine molecules named interferons (IFNs). Type I IFN-α has antiviral and 
immunostimulatory properties, and infection with high-risk HPVs downregulates its expression 
(25). As mentioned previously, HPV E6 and E7 have been implicated in immune evasion. Both 
oncoproteins suppress the type I IFN response by directly interacting with the components of the 
IFN signalling cascades (25, 45, 46). For example, E7 binds to and inactivates the interferon 
regulatory factor (IRF)-1, an IFN-β promoter binding transcription factor and an established 
tumour suppressor protein (45). E6 has been shown to bind to IRF-3 and this interaction is 
proposed to inhibit IRF-3 transcriptional activity, thus providing the virus with a way to evade the 
immune response of infected cells (47). HPV E5 causes retention of major histocompatibility 
(MHC) class I complexes (HLAs) in the Golgi apparatus and prevents their transport to the cell 
surface (18). Furthermore, E5 downregulates the surface expression of HLA-A and HLA-B 
molecules which present viral peptides to cytotoxic T lymphocytes (18). 
Despite these innate and early adaptive immune evasion strategies, HPV infection is cleared in 
most cases after several months by cell-mediated immunity, driven by a Th1-based immune 
response (18, 48). LCs take up viral antigens (made up of viral particles or proteins) from infected 
and dead keratinocytes (48). Subsequent activation of these LCs results in presentation of the 
antigen to naïve T-cells that become activated effector T-cells, capable of migrating to infected 
keratinocytes and destroying them (48).   
However, in 10 % of all cases, HPV infection is persistent, which greatly enhances the risk of 
progression to malignancy. As discussed previously, several co-factors contribute to this process. 
The major co-factor affecting South Africa is co-infection with the highly prevalent HIV. Both 




HPV infection in women at both the molecular and cellular levels, such as HPV entry into 
keratinocytes, establishment of persistent HPV infection, and immune evasion (49). HIV-1 
infection and low CD4 count have been shown to be significantly associated with increased risk 
of HPV infection and HPV-related disease progression. Immune response to HPV infection is 
modulated by CD4+ T cell-dominated Th1 response, therefore in HIV positive individuals who have 
low CD4 cell counts, HPV immune responses are dampened even further (14). As a result of 
increased risk of persistent HPV infection in HIV positive women, the risk of cancer development 
in HIV positive women increases. Indeed, HIV-infected women present with cervical cancer 15 
years earlier than HIV negative women (14). Usually, the administration of anti-retroviral therapy 
decreases the risk of AIDS-defining cancers (such as Kaposi’s sarcoma and non-Hodgkin’s 
lymphoma), but this is not the case for HPV-associated cancers (14).  
 
1.1.4 HPV prophylaxis and challenges 
To date, there is no treatment or cure for HPV infection. However, three highly efficacious 
prophylactic vaccines exist against the most common and high-risk HPV types. Gardasil® (Merck) 
was released in 2006, which provides protection against the high-risk HPV types 16 and 18, as 
well as HPV types 6 and 11, the latter being low-risk types which have been implicated in 90% of 
genital warts cases (50). Cervarix™ (GlaxoSmithKline) became available in 2007 to the public and 
prevents against the two major high-risk HPV types 16 and 18 (51). Merck later released an 
updated version of their vaccine in 2014, named Gardasil 9, which immunises against HPV types 
6, 11, 16, 18, 31, 33, 45, 52, and 58 (52).  
All of the above-mentioned vaccines are composed of virus-like particles (VLPs) derived from the 
spontaneous assembly of individual type-specific L1 capsid proteins (50–53). For this reason, the 
vaccines have little to no cross protection against other HPV types not included in the vaccine as 
the immune response is highly type-specific. Furthermore, these vaccines do not provide 
treatment for individuals who are already infected with HPV. The South African Department of 
Health (DOH) began a vaccination program and rolled out Cervarix™ to school girls (Grade 4, 




cytology screenings provided for women by the state, have not been sufficient to overcome the 
high HPV infection/cervical cancer rate in South Africa, due to financial and cultural strains (54). 
Many young girls are thought to have missed the opportunity to be immunised through the DOH 
vaccination programme as a result of absenteeism and limited access to school health teams (55). 
The need for a cold chain (controlled storage at low temperatures) has been difficult to maintain 
in South Africa and other LMIC countries with substandard infrastructure and low funding, which 
would more than likely make administration of vaccines to school girls in rural areas even more 
challenging (54).  
As the DOH program in South Africa is limited to young girls in the fourth grade of state schools, 
a large portion of young girls will not have had the opportunity to receive the vaccine through 
this programme. The likelihood of adolescent women being immunised outside of the school-
based programme is low as an adolescent health platform does not exist (54, 55). This means 
that little emphasis is put on increasing the knowledge and awareness around the need for 
vaccination to prevent HPV and cervical cancer in adolescent women. Many of those who are 
aware of the vaccine are challenged with the high cost of the vaccines (55).  
Another challenge faced by current HPV prevention by means of vaccination is the stigma and 
lack of knowledge surrounding cervical cancer, HPV and HPV vaccination, as well as reproductive 
health in general. A recent study was done on the understanding of cervical cancer, HPV and 
prevention among female students at a university in South Africa. It revealed that a large 
proportion of young women had limited knowledge of cervical cancer, HPV and vaccine 
availability (56). Some of the public have even raised concerns about the access to the HPV 
vaccines being an accelerator for girls’ sexual debuts, as well as a reason for young women to 
engage in increased sexual activity with a greater number of sexual partners. However, a study 
done in a cohort of college women in the US showed that there was no correlation between 
women receiving the vaccine and increased sexual activity at earlier ages (57). In many societies, 
especially in LMIC communities such as South Africa, pre-marital sexual activity is heavily frowned 
upon, which greatly decreases the likelihood of women seeking reproductive health care in 
medical facilities within their communities (58). All the above challenges greatly emphasise the 




Along with public education on HPV infection and prevention, alternative means of protection 
against HPV are needed which are broad-spectrum, more cost-effective and are easily accepted 
by the public. A clear example of this is the naturally derived sulphated polysaccharide 
carrageenan, which has been shown to inhibit early HPV infection by blocking viral attachment 
to cells (29, 59). Carrageenan has been formulated into the product Carraguard, a genital 
lubricant, where clinical trials have shown its use to be negatively associated with HPV infection, 
as well as with HSV-2 (60, 61). It did not, however, show any indications of prevention against 
vaginal transmission of HIV (62).  
There are several alternative approaches that could be investigated for the prevention of HPV 
and other sexually transmitted infections. One of which could be activation of the innate immune 
response to make HPV more “visible” to the innate immune system, thereby preventing epithelial 
cell infection, perhaps by designing drugs based on the molecular structure of innate opsonins 
(see section 1.2). Another approach would be to use molecules that bind to HPV, or the host cell-
surface molecules the virus uses for attachment and subsequent infection, in order to inhibit the 
virus/host interaction at the early steps of infection (see section 1.3). 
 
1.2 Enhancing immune recognition of HPV with surfactant proteins 
Surfactant proteins have been historically identified and described in the lung where they are 
part of the pulmonary surfactant, which is composed of a complex of phospholipids and proteins 
(63). Pulmonary surfactant is primarily responsible for reducing the surface tension at the air-
liquid interface of the lung (64). The four surfactant proteins (SPs) A, B, C, and D, make up 7% of 
the lung surfactant, with surfactant protein A (SP-A) making up the largest portion of this 
percentage (5.3%) (65). While SP-B and SP-C have vital roles in phospholipid packaging and 
reducing lung surface tension, SP-A and SP-D have been implicated in the innate immune 
response and have been shown to be opsonins of a variety of respiratory pathogens (66–68). As 
previous work from our laboratory indicated a novel role of SP-A for immune recognition of HPV, 





1.2.1 Structure of SP-A 
SP-A (and SP-D) are large hydrophilic proteins belonging to the collectins family. This family of 
proteins are soluble, collagenous C-type lectin pattern recognition receptors that tend to be 
calcium dependent (63). Their primary structure consists of an N-terminal non-collagenous 
domain capable of forming inter-subunit disulphide bonds, a collagenous region of Gly-X-Y 
repeats, a helical neck domain, and a globular C-terminal carbohydrate recognition domain (CRD) 
(63). Monomeric units spontaneously self-assemble into trimers and then form higher order SP-
A octadecamers (Figure 1.3) (69). SP-A preferentially binds to mannose, fucose and lipid ligands 
on the surface of incoming pathogens (70). SP-A has a very weak affinity to galactose and sialic 
acid which is important for distinguishing self from non-self, as these sugars usually form the 
terminals of carbohydrates on eukaryotic cells (70). SP-A (and SP-D) recognition and binding of 
their specific ligands usually takes place via their CRDs and elicits a variety of immune responses, 
including opsonisation and enhanced phagocytosis, regulating macrophage function and 
inflammation, and killing (70). 
 
 
Figure 1.3: Structure and assembly of SP-A. Monomers of SP-A are composed of a carbohydrate recognition domain 
(CRD), neck region, collagenous region and N-terminal region. These form trimers which then multimerise to form 






1.2.2 Interactions of SP-A with pathogens in the lung  
SP-A has been shown to have both pathogen recognition functions as well as a role in maintaining 
lung homeostasis. SP-A is able to recognise and bind pathogen associated molecular patterns 
(PAMPs) on the surface of bacteria. These usually comprise of clustered oligosaccharides (as 
described in section 1.2.1). In most instances, the recognition of bacterial PAMPs results in 
clearance of the infection. Studies have shown that SP-A mediates macrophage phagocytosis and 
neutrophil uptake of a number of bacteria, including of Escherichia coli (E. coli), Streptococcus 
pneumoniae (S. pneumoniae), Staphylococcus aureus (S. aureus), and Hemophilus influenza (H. 
influenza) (71). SP-A has also been shown to mediate Mycobacterium tuberculosis (M. tb) 
phagocytosis by alveolar macrophages, by binding to macrophage mannose receptors (67). 
Macrophages, however, serve as the major host cell niche for the growth and survival of M. tb, 
and so these results suggest SP-A assists M. tb growth and survival (72). SP-A has also been shown 
to play an important role in the pathogenesis of mucoid Pseudomonas aeruginosa (P. aeruginosa) 
infection in the lung in vivo, also by enhancing macrophage phagocytosis (73). 
SP-A has also been implicated in early innate immune responses to a variety of viral infections. 
Influenza A virus (IAV), a common respiratory tract infection, has been demonstrated to be 
controlled by SP-A. IAV clearance by SP-A is initiated by recognition of IAV glycoproteins 
haemaglutinin and neuramidase by the CRD of SP-A. This interaction leads to aggregation of the 
IAV particles, followed by enhanced neutrophil binding to the virus, resulting in clearance of IAV 
from the lung (74). SP-A has also been shown to have neutralising capabilities against respiratory 
syncytial virus (RSV) by binding to the F glycoprotein of RSV and blocking viral entry (68). It also 
recognises HSV-1 which generally infects the mucosal layer of the mouth, but can also cause 
infections in the respiratory tract (75). SP-A recognition of HSV-1 enhances viral uptake by 
alveolar macrophages.  
In addition to the recognition of viral and bacterial infection, SPs also play a role in the regulation 





1.2.3 Presence of SP-A in the female reproductive tract 
While SP-A has been historically identified in the lung where it plays an important role as an 
innate immune molecule protecting against pulmonary infections of a variety of pathogens (as 
outlined above), SP-A has recently been shown to express at various non-pulmonary sites (63). 
In the human female reproductive tract (FRT,) SP-A (and SP-D) has been detected in the 
myometrium, vaginal epithelium and vaginal lavage fluid (76, 77). It has been suggested that SPs 
play protective roles during pregnancy as well as contribute to innate defences against sexually 
transmitted pathogens (78, 79). It has recently been reported that supplementation with SP-A 
resulted in decreased uropathogenic E. coli growth in the urinary tracts of mice (80).   
SP-A (and SP-D) has been shown to interact with HIV via oligosaccharides on the HIV envelope 
protein gp120 in vitro (78, 81). SP-A binding to HIV inhibits its infectivity of CD4 T-cells, perhaps 
by blocking the CD4 binding site of gp120 (78). However, SP-A plays a dual role in HIV infection 
as SP-A was shown to enhance HIV uptake by DCs in vitro, where DCs transfer the virus to CD4 
cells, although no in vivo studies have validated this (81). 
 
1.2.4 SP-A enhances innate immune recognition of HPV16-PsVs 
In an attempt to identify novel molecules that enhance immune recognition of oncogenic HPV, 
our laboratory has demonstrated for the first time that SP-A binds directly to HPV16-PsVs (Figure 
1.4A), and that this binding was calcium dependent and independent of the lectin-binding 
domain (Ujma MSc thesis, 66). It was also shown that SP-D had little to no binding to HPV16-PsVs 
(Ujma MSc thesis, 66). To test whether this physical interaction between SP-A and HPV16-PsVs 
had any functional consequences on immune cell recognition, virus internalisation assays using 
the murine macrophage cell line RAW264.7 were performed. Pre-incubation of HPV16-PsVs with 
purified SP-A at a 1:10 (w/w) ratio prior to infection of RAW264.7 macrophages resulted in 
increased viral particle uptake (Figure 1.4B) (Ujma MSc thesis, 66). Infection assays revealed 
increased viral pseudogenome expression by RAW264.7 macrophages when HPV16-PsVs was 
pre-coated with SP-A (Figure 1.4C, (66)). Although overall infectivity of RAW264.7 macrophages 




incubation of HPV16-PsVs with SP-A had no effect on HeLa cell infection (Ujma MSc thesis, 66). 
To date, macrophages have not been shown to be infected by HPV, which explains the low levels 
of infection in RAW264.7 cells. It was therefore hypothesised that macrophages may prevent 
infection by effectively killing most of the internalised virus, and this was facilitated by exogenous 
addition of SP-A (Ujma MSc thesis, 66).  
Although the in vitro findings above elucidated a role of SP-A in enhancing immune recognition 
of incoming HPV16-PsVs, the HPV infection environment in the FRT is more intricate since a 
number of different cell types could be involved upon infection with HPV. For this reason a 
murine cervicovaginal challenge study model was used to elucidate the impact of SP-A on HPV16-
PsVs infection in a biologically relevant setting (29). Interestingly, SP-A was not detected in the 
murine FRT, neither in naïve C57BL/6 mice (Figure 1.4D) nor in HPV challenged mice (data not 
shown, Ujma MSc thesis (66). This was surprising as SP-A is known to be expressed in the FRT in 
humans (63). Furthermore, a preliminary mouse infection study indicated a reduction in HPV16-
PsVs infection for SP-A pre-incubated pseudovirions (Ujma MSc thesis 66). The data described 
above suggest a protective role of SP-A for HPV infection, and thus formed the basis for further 
studies on the effect of SP-A supplementation on HPV16-PsVs infection. These preliminary 
results, along with the results in this thesis, have recently been published in the journal 





Figure 1.4: Binding of HPV16-PsVs to SP-A results in increased viral uptake by RAW264.7 macrophages but not by 
HeLa cervical epithelial cells. [A] Co-immunoprecipitation experiments displaying the input, flow through (FT) and 
eluate samples of HPV16-PsVs incubated with SP-A. Complexes were incubated for 1 hour at 4°C, followed by 
precipitations with anti-HPV16-L1 (CamVir) or anti-SP-A antibodies. Western Blots were performed using the CamVir 
antibody to detect the presence of HPV16-L1. [B] RAW264.7 cells were infected with fluorescently labelled HPV16-
PsVs (pre-absorbed with SP-A or BSA control where indicated) for 1 hour at 37°C. Cells were washed extensively and 
lifted with trypsin/EDTA to remove surface-bound virions and subjected to flow cytometry to quantify viral 
internalisation. Experiments were performed in triplicate, quantified by quadrant analysis of the dot blots of three 
independent experiments and presented as x-fold increase relative to the mean fluorescence intensity of cells 
infected with untreated HPV16-PsVs which was set as 1. Significances were calculated by means of one-way ANOVA 
and Tukey post-hoc tests. *** indicates statistical significance between uptake of HPV16-PsVs in the presence of SP-
A as compared to the other tested conditions (*** = p<0.001). [C] RAW264.7 and HeLa were infected with HPV16-
PsVs encapsidating the firefly luciferase reporter plasmid pGL3-control for 48 hours. Where indicated, the viral 
particles were pre-absorbed with purified SP-A protein (or BSA control) before infection. Firefly luciferase activity in 
the cell lysates as a measure for successful infection is presented as Relative Light Units relative to RAW264.7 cells 
infected with untreated HPV16-PsVs which was set as 1. Bars in [B] and [C] depict mean values, with error bars 
showing SEM. [D] Western Blot assessing SP-A expression in lung, bronchoalveolar lavage fluid (BAL), female 
reproductive tract (FRT) tissue, and vaginal lavage (vag. lavage) fluid of naïve wildtype C57BL/6 mice. 20µg of each 






1.3 Modulation of the interaction between HPV and host cell surface molecules by vimentin 
1.3.1 The intermediate filament vimentin 
The cytoskeleton of mammalian cells provides structural integrity and support to their largely 
aqueous and susceptible internal constituents. Three major cytoskeletal networks run through 
vertebrate cells, namely actin/micro- filaments (MF), microtubules (MT) and intermediate 
filaments (IF). Intermediate filaments have been termed due to their diameter (10nm) being 
between that of actin microfilaments (7-10nm) and microtubules (24nm) in metazoan cells (83, 
84).   
IFs, the least structurally characterised of the three filament systems, are expressed by a large 
family of at least 65 genes that produce minor variations of a homologously conserved polymer 
structure, suggesting its vital role in cellular physiology (85–87). They are divided into 5 types (I 
to V), based on the properties of their amino acid sequences. Of those, vimentin is the major 
constituent of all the type III IFs which additionally include desmin, glial fibrillary acidic protein, 
and peripherin (84). Vimentin is present in cultured fibroblasts, endothelial cells, lymphocytes, 
and epithelial cells, which are cells with a mesenchymal heritage (88–90). Importantly, 
vimentin is the sole IF that exists in almost all sarcomas, meningiomas, schwannomas, 
and melanomas, giving evidence to its crucial role in cancer cell biology and making it a promising 
cancer diagnostic marker (90).  
 
1.3.2 Cellular functions of vimentin 
It has taken some time for researchers to understand the importance of this intermediate 
filament protein, mainly because vimentin knockout mice expressed a very mild phenotype and 
initially appeared healthy (91). Further studies revealed vimentin’s role in a variety of cellular 
functions ranging from integrating into the entire cytoskeleton, responding to mechanical stress, 
cellular adhesion, to signalling (92, 93). It appears that vimentin is able to help the cell respond 
to stress in a variety of forms, including heat, infection, and toxins (94, 95). The highly complex 





As a characteristic protein of cells of mesenchymal origin, the expression of vimentin 
correspondingly increases in cells transitioning from an epithelial to mesenchymal state (EMT). 
EMT is associated with increased motility and is important during development, wound healing 
and during cancer invasion and metastasis (97). Vimentin has also been shown to play a crucial 
role in transcellular migration of lymphocytes across endothelial cells (98). Mice lacking vimentin 
displayed lymphocytes with retarded homing and ability to adhere and cross the endothelium 
(98). In addition, vimentin has been shown to be a central player in the programmed cell death 
process of apoptosis, as cleavage of intracellular vimentin leads the way into cellular breakdown 
(99).  
 
1.3.3 Structure of vimentin 
The structural organisation of a vimentin monomer is composed of a central α-helical rod 
domain, flanked by an intrinsically disordered N-terminal (“head”) and a C-terminal (“tail”) 
domain (74, 75). The monomers are fairly stable in denaturing conditions, and spontaneously 
assemble into coiled-coil dimers, followed by assembly of two of these dimers into antiparallel 
tetramers (Figure 1.5) (101). It has been shown in vitro that the assembly of the vimentin 
tetramers into full-length filaments is instigated by the addition of monovalent salts, such as 
potassium chloride (KCl) and sodium chloride (NaCl) (101, 102). Typically, eight of these 
tetramers further associate laterally to form what is called a unit length filament (ULF). ULFs can 
associate end to end to form longer filaments, however, it is not precisely known what the exact 





Figure 1.5: Structure of vimentin filaments. The vimentin monomer, consisting of an elongated rod domain flanked 
by a “head” N-terminal domain and “tail” C-terminal domain, spontaneously form dimers. Two dimers associate 
laterally to form an offset tetramer. Eight tetramers associate to form a unit length filament (ULF). Figure adapted 
from (103). 
 
1.3.4 Interactions of surface-expressed and secreted vimentin with pathogens 
Although best described as a cytosolic protein involved in cellular processes such as cell adhesion 
and cell migration, vimentin has been identified on the surface as well as in the extracellular 
spaces of cells of various origins (104–107). However, the biological role of cell surface and 
secreted vimentin is only beginning to be elucidated. Levels of surface expression have been 
shown to be altered during the cell cycle, and differ among cell lines (108). In addition, cell surface 
vimentin functions as an endogenous, activating ligand for Dectin-1, a non-toll like pattern 
recognition receptor, present on inflammatory cells (109). Here, it has been linked to the 
inflammation of the arterial wall and oxygen production, suggesting that by activating Dectin-1 it 
contributes to the oxidation of lipids and cholesterol accumulation in atherosclerosis (109). 
Promisingly, cell surface vimentin has the potential to be exploited as a marker for detecting 




In addition to vimentin’s diverse roles described above, vimentin has also been observed to be 
affected by, or play a role in infection of, a variety of pathogens. It has been shown that vimentin 
is secreted by macrophages in response to pro-inflammatory cytokines produced as a response 
to E. coli infection, where the secreted vimentin interacts with E. coli and favours bacterial killing 
(106). In contrast, several bacterial pathogens have been shown to utilise vimentin for successful 
infection. Anaplasma phagocytophilum (A. phagocytophilum) infection induces re-organisation 
of the vimentin filament network and this is necessary for infection (111). C. trachomatis 
replicates within a membrane-bound vacuole termed an ‘‘inclusion’’ (112). Vimentin and other 
intermediate filaments are also reorganised upon C. trachomatis infection, where this has been 
shown to be necessary for maintaining the structural integrity of the inclusion, and was 
hypothesised to also hinder the exposure of C. trachomatis to the innate immune system (112). 
Many viruses have been described to utilise the vimentin protein network for cell surface 
attachment and entry, which is often accompanied by drastic changes in intermediate filament 
arrangement. Cowpea mosaic virus (CPMV) is one such virus that utilises cell surface vimentin to 
attach to its host cells. CPMV is a plant Comovirus and a member of the Picornavirus superfamily 
(113). Vimentin was shown to bind to CPMV, and knocking down vimentin resulted in reduced 
infection by CPMV (113).  
Japanese encephalitis virus (JEV), a mosquito born Flavivirus, was found to interact with vimentin 
(114). The role of vimentin as a receptor for viral entry was then validated when an antibody 
against vimentin resulted in inhibition of cellular entry of JEV into porcine kidney cells, possibly 
by disrupting the binding of the JEV envelope protein to vimentin (115). This interaction was not 
observed in other cell lines tested (114). Furthermore, it was found that JEV infection was 
attenuated upon vimentin knockdown (115). These studies infer a crucial role for vimentin in 
entry of JEV into certain mammalian cells.   
The entry of the ubiquitous Human Cytomegalovirus (CMV) into fibroblasts is also affected by a 
lack of vimentin (116). CMV is a herpesvirus that can cause grave complications when present in 
immunocompromised individuals. Studies in human fibroblasts showed that disarrangement of 




cellular entry with two disparate strains of CMV, one with a restricted and another with a wide 
cell tropism (116). 
Enterovirus 71 (EV71) is a highly transmissible single-stranded RNA virus that belongs to the 
human enterovirus species A of the genus Enterovirus within the Picornaviridae family (117).  
Infection with EV71 results in extreme central nervous system malfunction in infected infants and 
small children (117). It was shown that the N-terminus portion of vimentin filaments is involved 
in binding to EV71 on the host cell surface, and blocking  vimentin using either soluble vimentin, 
or antibodies resulted in reduced binding of EV71 to the cell surface (117). 
A novel Coronavirus was implicated as the etiological agent of severe acute respiratory syndrome 
(SARS), a life threatening respiratory illness, and therefore named SARS-CoV (118). SARS-CoV has 
been detected in the lung, bronchi, trachea, and surprisingly in non-respiratory tissues as well 
(119). SARS-CoV binds to the angiotensin-converting enzyme 2 (ACE2), the type I integral 
transmembrane protein, for cellular entry (120). ACE2, however, is not adequate enough for 
maintaining viral infection. Vimentin was shown to be a cellular factor that is copiously present 
in the SARS-CoV spike protein-ACE2 complexes (121). Vimentin was shown to directly bind to the 
SARS-CoV spike protein in kidney epithelial cells and has been shown to  play an essential role in 
the cellular entry of SARS-CoV (121).  
 
1.3.5 Interactions of HPV and vimentin 
A study done by Schäfer et al aimed to discover novel host surface molecules that interact with 
high-risk HPV16 with the aim to modulate infection (36). Biochemical pull-down experiments 
showed that surface-expressed vimentin interacted with HPV16-PsVs, regardless of whether the 
pseudovirions underwent furin cleavage, a step shown to be necessary for successful infection 
(Figure 1.6A) (36, 37, 40). Unlike most viruses that use vimentin to aid in internalisation, this study 
demonstrated that both surface-expressed and recombinant human vimentin (rhVim) functioned 
as an inhibitory molecule for HPV16-PsVs entry. When HeLa, HaCaT and NIKS cells1 were 
 
1 All cell lines representing physiologically relevant cell culture models, where NIKS in particular have been found 




challenged with HPV16-PsVs that were pre-incubated with rhVim prior to infection, infectious 
internalisation was significantly lower when compared to the BSA control across all cell lines 
(Figure 1.6B) (36). Knockdown of surface vimentin of NIKS cells led to an increase in HPV16-PsVs 
infection, which was more pronounced when HPV16-PsVs underwent furin treatment (36). 
Conversely, transient overexpression of surface vimentin significantly decreased HPV16-PsVs 
binding, uptake, and infection of NIKS cells, which was independent of furin treatment (36).  
Schäfer et al hypothesised that both cell surface or soluble vimentin bind to viral particles and 
modulates the early steps of HPV infection (i.e. cell surface binding and cellular entry) either by 
masking portions of the virus necessary for interactions with cell surface molecules/receptors, or 
by causing steric hindrance which would destabilise, or prevent host-virus interactions necessary 
for infectious internalisation (36). Further characterisation of the mechanisms by which artificial 
supplementation with rhVim modulates HPV16-PsVs infection may enable the development of 










Figure 1.6: Identification of cell surface and recombinant human vimentin (rhVim) as binding proteins for HPV16-
PsVs, modulating HPV16-PsVs infection in vitro (36). [A] Western Blot (left gel) of a pull-down experiment (pgsD677 0 F2 
surface proteins bound to furin pre-cleaved (FPC)-HPV16-PsVs pulled-down by the HPV16-L1 specific antibody 
CamVir1), probed simultaneously with the anti-vimentin antibodies H84 and V9 (upper panel) and re-probed with 
the antibody CamVir1 (lower panel). Note that in the presence of HPV16-PsVs the size of the vimentin protein is 
slightly reduced. IN, input; FT, flow-through; Elu, eluate. Pull-down of HPV16-PsVs (with or without furin pre-
treatment) using immobilised rhVim (right gel). Proteins were detected by Western Blot using the antibody CamVir1. 
[B] AF488-conjugated HPV16-PsVs (with or without prior furin cleavage) were pre-treated with soluble rhVim or BSA 
before infection of HeLa, HaCaT and NIKS cells. Internalisation of viral particles was assessed by flow cytometry and 
presented as change in mean fluorescence intensities of AF488-positive cells compared to untreated particles which 
was set as 100%. Quadrant statistics of three independent experiments performed in triplicate were used to 
calculate the means ± S.D. with the Student’s t test used for determination of statistical significance compared to 
controls (* = p<0.05). Figure adapted from (36). 
 
 
2 In order to biochemically pull-down surface molecules that interact with HPV16-PsVs, the HSPG-deficient 
pgsD677 cell line was used. This, along with furin pre-cleavage of the HPV16-PsVS, allowed for the bypassing of the 





Hypothesis 1: Purified human SP-A protein reduces HPV16-PsVs infection by enhancing immune 
recognition of the virions by recruitment of innate immune cells to the site of infection, resulting 
in immune cell uptake of viral particles. 
Hypothesis 2: RhVim modulates HPV16-PsVs infection by interfering with the early (and crucial) 
steps of HPV infection, namely cell-surface binding and internalisation, by preventing receptor-
virus binding necessary for successful infection.  
 
1.5 Aims and Objectives 
Aim 1: To further characterise the mechanisms elicited by purified SP-A in reducing HPV16-PsVs 
infection through enhancing immune recognition of HPV16-PsVs using an established in vivo 
mouse cervicovaginal challenge model. 
 
This aim will be addressed by the following two objectives: 
• To determine whether SP-A enhances recruitment of macrophages in HPV16-PsVs infected 
mouse FRT tissue. 
• To set up an adaptation of the HPV16-PsVs cervicovaginal challenge model (29) in order to 
observe the effects of SP-A on the FRT innate immune cell populations1F3 by flow cytometry of 
both HPV16-PsVs infected and uninfected tissue, as well as to establish any changes in viral 










Aim 2: To further characterise rhVim in its ability to modulate the early events of HPV cellular 
entry and infection, using both in vitro and in vivo approaches. 
 
This aim will be addressed by the following two objectives: 
• To determine whether the structure of rhVim (filamentous or globular) affects its ability to 
reduce HPV16-PsVs infection in vitro and in vivo using an established mouse cervicovaginal 
challenge model (29) 
• To determine if rhVim has an effect on HPV16-PsVs surface binding and internalisation in the 


















2 Materials and methods 
2.1 General materials  
Chemicals of analytical/reagent grade were used and generally purchased by Merck, or Sigma 
Aldrich, unless indicated otherwise. Solutions made up in the laboratory are detailed in the 
Appendix. 
 
2.2  Cell culture 
The human keratinocyte cell line NIKS (ATCC CRL-12191) was cultured in complete F-Medium 
(Appendix) and the virus packaging cell line HEK293TT (122, 123) as well as the human epithelial 
cervical adenocarcinoma cell line HeLa (ATCC® CCL-2™) were cultured in complete Dulbecco’s 
Modified Eagle Medium (DMEM) (Appendix). Cell culture procedures were performed under 
sterile conditions to prevent the risk of contamination. 
All cells were cultured in 75cm2 cell culture flasks (SPL Life Sciences) and incubated in a humidified 
atmosphere containing 5% CO2 at 37°C. Cells were passaged as follows:  
The old media was removed from the cells followed by adding 5mL 0.025% trypsin/0.01% 
Ethylenediaminetetraacetic acid (EDTA) in phosphate buffered saline (PBS) for 5 to 15 minutes 2F4 
at 37°C, to lift the cells from the flask. 5mL F-medium, or complete DMEM was then added to the 
respective cells in order to stop the trypsin/EDTA reaction. The cell suspensions were transferred 
to 15mL Falcon tubes (SPL Life Sciences), where the cells were pelleted by centrifugation 
(2800rpm for 2 minutes). The cell pellets were re-suspended in 10mL of their respective growth 
medium, where 2 to 3mL of the resuspended cells was transferred to a 75cm2 cell culture flask, 
along with 10mL of sterile medium. Cells were passaged twice a week, to allow the cells to reach 
approximately 80% confluency. 
Where precise numbers of viable cells were required before seeding, manual cell counting by 
means of a counting chamber and trypan blue staining were used. 10μL cell suspension was 
 
4 The HEK293TT and HeLa cell lines required approximately 5 minutes of trypsinisation before all the cells lifted 




added to 90μL trypan blue (Appendix), which allows for the distinguishing of viable and dead cells 
as the blue dye enters the porous membrane of the dead cells. 10μL of this solution was placed 
on a Neubauer hemocytometer (Marienfeld) and covered with a glass coverslip. Bright unstained 
live cells were counted using a microscope (Nikon TMS) and cell concentration was determined 
using the following calculation: 
  
The cell densities for each experimental procedure are described below. 
 
2.3 Studying HPV infection using HPV16-PsVs 
To study HPV16 infection in vitro and in vivo, non-oncogenic infectious HPV16 pseudovirions 
(HPV16-PsVs) were generated according to a procedure by Christopher Buck (122). These 
pseudovirions encapsidate a reporter plasmid representing the pseudogenome, which allows for 
the quantification of infection once the pseudovirions have successfully infected cells and 
reached the host cell nucleus. HPV16-PsVs particles containing the Gaussia luciferase (GLuc) 
reporter plasmid pCMV-GLuc 2 (New England Biolabs) were used to measure infection. Gaussia 
luciferase is an oxidative enzyme originally produced by the marine copepod Gaussia princeps, 
and contains an internal signal peptide for extracellular secretion (124). Because this protein is 
secreted from the cell cytoplasm, using HPV pseudoparticles encapsidating Gaussia luciferase can 
be beneficial for certain experiments, such as time course experiments, as luciferase activity can 
be measured directly from cell supernatants or from body fluids (such as vaginal lavages) without 
needing to lyse cells or sacrifice the animal (see section 2.7) (66). 
Fluorescently labelled HPV16-PsVs particles (AF488-HPV16-PsVs) were also used to determine 




experiments, Alexa Fluor 488 (AF488) was used to fluorescently label HPV16-PsVs (see section 
2.3.2). 
 
2.3.1 Production of HPV16-PsVs 
To produce HPV16-PsVs, HEK293TT cells were plated on a total of 16 10cm dishes, and co-
transfected with the pXULL plasmid (122) (which encodes codon-optimised HPV16 L1 and L2 
capsid proteins) and the pCMV-GLuc 2 plasmid (the Gaussia luciferase reporter plasmid), using 
the calcium phosphate method described in previous studies (122, 125). 48 hours later, the cells 
were harvested by trypsinisation and pelleted by centrifugation (2000rpm for 2 minutes) in a 
50mL Falcon tube. The cell pellet was resuspended in 1mL 1X PBS and transferred to a 1.5mL 
siliconised Eppendorf tube 3F5. 
The cells were centrifuged again (3000rpm for 5 minutes), before being resuspended in a 1:1 (v:v) 
of PBS and 9.5mM MgCl2. 1/20 Vol fresh 5% Brij58 was added in order to lyse the cells, and 1μL 
Benzonase and 1μL Exonuclease V (New England Biolabs) was added to digest any un-
encapsidated DNA  (66, 122). 
 The solution was incubated at 37°C for 24 hours, where the solution was occasionally mixed to 
allow for particle maturation. The lysate was then chilled on ice and 0.17 Vol PBS + 5M NaCl was 
added, followed by three freeze/thawing cycles at -80°C/25°C (66). The lysate was then 
centrifuged at 8000g for 10 minutes at 4°C to pellet any cell debris, followed by AF488 labelling 
(for confocal and flow cytometry analysis, section 2.3.2) and HPV16-PsVs purification (section 
2.3.3). 
 
2.3.2 HPV16-PsVs labelling with Alexa Fluor 488 
HPV16-PsVs particles were fluorescently labelled with AF488 succinimidyl ester (Invitrogen)  
before CsCl (caesium chloride) gradient purification, as described in Bergant et al. (126). Before 
fluorescently labelling the viral particles (produced as described in 2.3.1.), the pH of the lysate 
 




was adjusted by adding 1/10 Vol 1M NaHCO3, to a final pH of 8.8. 1/10 Vol AF488 (10mg/mL in 
DMSO) was then added to the cell lysate before incubating for 1 hour at room temperature with 
continuous rotation. Thereafter, the lysate was adjusted to pH 6.5 using 1/25 Vol 1M NaPO4 
(126).  
 
2.3.3 HPV16-PsVs purification 
CsCl ultracentrifugation was used to isolate the HPV16-PsVs from cell lysates (66). This was 
achieved by loading the lysate onto a discontinuous CsCl gradient. 4mL light CsCl (1.25g/mL in 1X 
HSB, see Appendix) was loaded to a 13.2mL Ultra-Clear™ centrifuge tube (Beckman Coulter), 
followed by carefully adding 4mL heavy CsCl (1.4g/mL in 1 X HSB) underneath the light CsCl layer 
(Appendix). The cell lysate was then made up to 3.5mL with 1 X HSB buffer and gently placed on 
top of the CsCl gradient. Tubes were centrifuged between 16 and 18 hours at 20 000rpm in a 
Beckman SW40Ti swinging bucket rotor. Viral particles were harvested from the gradient by 
inserting an 18-gauge needle attached to a 5mL syringe into the tube just below the interface. 
The sample, now containing the pseudovirions, was then transferred to an Amicon Ultra-4 
Centrifugal filter unit (Millipore) and centrifuged at 3000rpm for 10 minutes, to concentrate the 
pseudovirions. The pseudovirions were then rinsed with 3mL HSB buffer and centrifuged at 
3000rpm for 10 minutes, or until the sample was concentrated to approximately 100mL. The 
protein concentration of HPV16-PsVs preparations was then quantified using the Pierce™ BCA 
Protein Assay Kit (Thermo Scientific), according the manufacturer’s instructions. HPV16-PsVs and 
AF488-HPV16-PsVs preparations were stored at -80°C in siliconised 1.5mL Eppendorf tubes. 
 
2.3.4 Quality checks of HPV16-PsVs preparations 
2.3.4.1 SDS-PAGE and silver staining 
SDS-PAGE gels were used to determine the purity of HPV16-PsVs preparations. 3μL of each 
HPV16-PsVs preparation was loaded and electrophoresed according to conventional protocols 
(4,5). AF488-HPV16-PsVs preparations were visualised using a Biospectrum™ 500 Imaging System 




AF488 labelled L1 and L2 capsid proteins, respectively, with the L1 protein being at a 10-fold 
excess compared to L2 (122). Gels were then stained to visualise the L1 and L2 proteins (as well 
as any possible impurities) of the HPV16-PsVs using the Pierce™ Silver Stain Kit (Thermo 
Scientific), according to the manufacturer’s instructions. 
 
2.3.4.2 Luciferase infection assay 
Luciferase assays were performed to determine the infectivity of HPV16-PsVs preparations, and 
for measuring infection in vivo under various experimental conditions (section 2.7.1). For quality 
control purposes, HeLa cells were seeded as described in Schäfer et al 2017 (36), where the 
following luciferase infection assays were performed: 
• HPV16-PsVs only 
• Positive control: HPV16-PsVs pre-incubated for 1 hour at 4°C with the HPV16 neutralising 
antibody H16.V54F6 . This was expected to abolish infection. 
• HPV16-PsVs treated for 1 hour at 37°C with DNase I endonuclease (Thermo Scientific). This 
would cleave any plasmid that was not packaged in the viral capsid, so any measured luciferase 
was due to infection only. 
To measure infection, 5μL cell supernatant (or vaginal lavage, see section 2.7.1) was added to a 
white 96-well plate (Nunc) and measured using a GloMax® Explorer Multimode Microplate 
Reader (Promega) following the Gaussia Luciferase Assay Kit (New England Biolabs) protocol. Per 
sample, freshly prepared GLuc Assay Solution consisting of 0.5μL BioLux GLuc Substrate added to 
50μL BioLux Assay Buffer (New England Biolabs) was added per well and luminescence measured 
with 2 seconds lag time over 10 seconds integration time. 
 
 




2.4 Negative staining transmission electron microscopy 
Negative staining transmission electron microscopy (TEM) was employed to visualise viral 
particles as well as to determine the structure of recombinant human vimentin (rhVim) under 
various conditions. Samples of 0.08μg/μL rhVim and NaCl with concentrations ranging from 0mM 
to 100mM were pre-incubated for 1 hour before negative staining and viewed as described 
below. Samples of HPV16-PsVs were made to a final concentration of 0.08μg/μL as subsequent 
rhVim experiments used a 1:1 molecular ratio to the L1 protein of the HPV16-PsVs (see section 
2.5 for details). 
With the assistance of Dr Mohamed Jaffer from the UCT Electron Microscope Unit, samples were 
analysed as described in Varsani et al 2007 (128). 3μL of sample was absorbed onto a carbon-
coated copper grid (Agar Scientific) and left for 30 seconds before blotting with filter paper. The 
carbon-coated copper grid had been glow-discharged using the Glow Discharge Unit (Agar 
Scientific) to render the carbon surface hydrophilic, allowing for the sample to adhere to the grid. 
The sample was then washed twice with a drop of deionised water, blotting with filter paper after 
each application, and subsequently stained with 2 drops of 2% aqueous uranyl acetate (SPI 
supplies), followed by blotting with filter paper. The grid was air-dried before being viewed with 
a Philips Tecnai F20 equipped with a field emission gun operating at 200kV. Images were taken 
with a Gatan US 4000 4kX4k CCD camera using the Digital Micrograph software suite. 
 
2.5 Viral binding and internalisation assays  
Various flow cytometry experiments were conducted to quantify viral internalisation and binding 
of NIKS cells. These involved using AF488-HPV16-PsVs, as AF488 emits fluorescence when excited 
by a 488 nm laser, allowing for detection of any bound or internalised virus. All conditions tested 
were performed in triplicate on NIKS cells, with three independent biological repeats for each 
experiment. 
For virus binding and internalisation assays, NIKS cells were seeded in 12-well plates (Greiner Bio-
One) at a density of 5x103 cells per well and incubated overnight at 37°C. Before addition to cells, 




(w/w)5F7, unless stated otherwise) for 1 hour at room temperature. Where indicated, 
pseudovirus/protein incubations occurred in the presence of varying concentrations of NaCl (0-
100mM) and/or in the presence 3% carboxymethyl cellulose (CMC).  
Moreover, to determine the effect of HSPGs on virion internalisation, NIKS cells were treated 
with heparinase I (Sigma, derived from Flavobacterium heparinum) before binding and 
internalisation assays were performed. Briefly, NIKS cells were treated, rinsed and covered with 
KCl isotonic buffer (Appendix) before adding 5U of heparinase I per well  for 1 hour at 37°C (32). 
Cells were washed three times with 1X PBS before adding fresh F-media and the pre-incubated 
virions. Successful removal of HSPGs was determined by confocal microscopy (see section 2.6). 
Cells were infected with pre-incubated AF488-HPV16-PsVs for 30 minutes at 37°C in order to 
achieve internalisation of the pseudovirions, or for 1 hour at 4°C to achieve pseudovirus cell-
surface binding. Following infection, medium was aspirated from each well and cells were 
washed 3 times with 1X PBS. With regards to internalisation assays, cells were harvested by 
incubating cells with 300μL trypsin/EDTA for 15 minutes at 37°C, which removed any cell-surface 
bound virus and therefore allowed for quantification of internalisation only (36). For binding 
assays, cells were harvested by incubating with 300μL lidocaine/EDTA for 15 minutes at 37°C, 
which does not remove any cell-surface bound AF488-HPV16-PsVs, allowing for quantification of 
cell-surface binding (36).  
Once all the cells had been lifted, 400μL F-medium was then added to each well to neutralise the 
trypsin or lidocaine reactions. Cell suspensions were transferred to 1.5mL Eppendorf tubes and 
centrifuged at 700g for 2 minutes at 4°C. The supernatant was removed, and each cell pellet 
resuspended in 500μL FACS wash (Appendix). Cells were centrifuged at 700g for 2 minutes at 4°C 
and the supernatant removed. Cells were fixed by resuspending the cell pellets in 100-300μL 
FACS fix (Appendix) and samples were subjected to a short spin in a microcentrifuge before being 
 
7 A 1:1 (w/w) for rhVim and HPV16-PsVs is equivalent to a 1:1 (mol/mol) for rhVim and the L1 capsid protein:  
1 ng rhVim (54.3 kDa) = 1.1x1010 rhVim molecules. 
1 ng L1-only HPV particles (20 000 kDa) = 30x106 HPV virions. Assuming each particle contains 72x5 L1 molecules 
(145), the number of molecules in 1 ng of HPV L1-only particles is 1.08x1010 . 
Therefore, when using vimentin and HPV particles at a 1:1 (w/w) ratio the molar ration between 1 molecule 
vimentin and 1 molecule L1 is approximately also 1:1. 




transferred to 5mL polystyrene round-bottom tubes (Falcon) and kept in the dark at 4°C until 
analysis to prevent fading of the AF488 fluorescence. 
Data were acquired using a BD FACSCalibur™ together with the BD CellQuest™ Pro software 
(Version 5.2.1, BD Biosciences), and at a later stage with a BD LSRFortessa™ together with BD 
FACSDiva™ software. Acquisition parameters were determined using uninfected cells (negative 
control). The cell population was gated using the dot plot showing forward scatter (FSC) versus 
side scatter (SSC) of the negative control using the BD FlowJo™ software. Gating was performed 
to exclude any contaminants and cell debris. Dot plots of fluorescence in the FL1 channel (AF488 
positive cells) versus SSC were generated in BD FlowJo™ and quadrant statistics determined (see 
Supplementary Figure 1). 
Statistical analysis was performed on the percentage of AF488 positive cells (cells observed in the 
lower right quadrant) for the gated cell population. Data was assessed for normality using the 
Shapiro-Wilk test in STATA. One-way analysis of variance (ANOVA) and Tukey post-hoc tests were 
performed using Graph Pad Prism 5 or 8 (Graph Pad Software), to determine the differences in 
viral internalisation and binding between different conditions tested. 
 
2.6 Staining of surface HSPGs on HPV16-PsVs infected NIKS cells 
In order to visualise surface HSPGs on NIKS cells by immunohistochemistry (IHC), NIKS cells were 
seeded in 12-well plates (Greiner Bio-One) containing sterile round coverslips (Marienfeld) at a 
density of 5x103 cells per well and incubated overnight at 37°C. The cells were either infected as 
described in section 2.5, or left untreated, before being  rinsed in cold F-medium and incubated 
with a mouse anti-heparan sulphate monoclonal antibody (Seigaku, 10E4 epitope) at a dilution 
of 1:100 for 1 hour at 4°C. Cells were rinsed with cold 1X PBS and fixed with 4% (v/v) 
paraformaldehyde in 1X PBS for 10 minutes at room temperature, before being washed 3 times 
for 5 minutes with 1X PBS and blocked with blocking solution (Appendix) for 1 hour at room 
temperature.  
Cells were then stained with an AF647-conjugated donkey anti-goat antibody (Jackson 




room temperature. The cells were rinsed with 1X PBS prior to being counterstained with Hoechst 
(Sigma) at a dilution of 1:6000 in 1X PBS. Cells were washed with 1X PBS and mounted on glass 
slides with Mowiol (Sigma) containing n-propylgallate for its anti-fade properties. Slides were 
stored at 4°C protected from light until viewing.  
Slides were viewed using a Zeiss LSM880 Airyscan confocal microscope together with Zen 2.3 SP1 
software (Zeiss). Co-localisation analysis was performed for each optical section in z-stacks of 
individual cells. Quantification of co-localisation was performed on approximately 50 cells for 
each experimental condition tested, using the Zen software. Co-localisation coefficients for the 
fluorescence channels representing AF647-labeled heparan sulphates and AF488-labeled HPV16-
PsVs, respectively, as well as overlap coefficients were determined according to the method of 
Manders et al. (129). 
Z-stack dimensions were then normalised to 10 optical sections per image stack, and maximum 
intensity projections were done for display purposes. The lower and upper thresholds were set 
at 14 and 230 greyscale levels, respectively, for each maximum intensity projection. This was 
done to remove background signal so that the measured signal for AF647 corresponded to the 
area representing 10E4 Heparan Sulphate staining. 
 
2.7 In vivo infection of female C57BL/6 mice with HPV16-PsVs 
In order to study the effects of rhVim and SP-A on HPV16 infection in vivo, a murine cervicovaginal 
challenge model was applied as described by Roberts et al (29). All in vivo experiments were 
performed on female, 6 to 10 week-old C57BL/6 mice. The mice were housed and monitored in 
the UCT Research Animal Facility (RAF) Biosafety Level 2 laboratory, as described in (66). All 
experiments were approved by the Faculty of Health Sciences Research Animal Committee at 
UCT (ethics number: 016/008). 
4 days prior to infection, mice were injected subcutaneously (s.c.) with 100μL 2mg/20g Depo-
Provera (Pfizer) in sterile 1X PBS to equilibrate hormone levels as well as to help facilitate 
infection by thinning the vaginal epithelium (Figure 2.1) (29). 6 hours before infection, mice were 




0.2mg/20g xylazine. Following this, vaginal lavages were performed with 2X 50μL sterile 1X PBS. 
25μL 4% nonoxynol-9 (N-9, US Pharmacopeia) in 3% carboxymethylcellulose (CMC) was then 
added to the genital tract, as N-9 is known to chemically disrupt the vaginal and cervical 
epithelium, facilitating HPV infection (130). After 6 hours, mice were anaesthetised as described 
above and infected intravaginally (i.vag.) with 1μg HPV16-PsVs encapsidating the pGluc reporter 
gene (pre-incubated with rhVim or SP-A as indicated) in 3% CMC. For time course experiments, 
vaginal lavages were performed daily with 2X 50μL sterile 1X PBS and stored at -80°C until 
analysis.  
Mice were euthanised using halothane 3 days post infection (p.i.), followed by cervical dislocation 
as a confirmation of death. For early infection experiments (see sections 2.7.2 and 2.7.3), mice 
were euthanised 2 hours p.i. (h.p.i.) and the genital tract dissected. Briefly, using dissection tools, 
the peritoneal cavity was opened, and the cecum and colon was moved to expose the genital 
tract. The bladder was then excised from the vagina, and the genital tract removed from the body 
cavity. Fat and connective tissue were then carefully removed from the genital tract tissue. The 
fallopian tubes and ovaries were removed, and the remaining genital tract, which included the 





Figure 2.1: Mouse model for HPV16-PsVs infection using C57BL/6 mice, adapted from Roberts et al. (29). 
 
2.7.1 Processing of samples from HPV16-PsVs infected female C57BL/6 mice 
To measure luciferase activity in the vaginal lavages of mice infected with GLuc HPV16-PsVs, the 
vaginal lavages collected in Eppendorf tubes were centrifuged for 1 minute at 700g to remove 
any vaginal mucus from the sample. Thereafter, 5μL lavage was added directly to a white 96-well 
plate and measured using a Fluoroskan™ Ascent Microplate Fluorometer and Luminometer 
(Thermo Scientific) or a GloMax® Explorer Multimode Microplate Reader (Promega) following 









2.7.2 Flow cytometry analysis of HPV16-PsVs infected mouse FRT single cell suspensions 
In order to recapitulate the early events of human sexual HPV transmission and elucidate the 
early immune responses subsequent to infection with SP-A pre-incubated viral particles, different 
approaches were followed involving single cell suspensions prepared from female reproductive 
tracts of mice treated as outlined below. Cells were analysed by flow cytometry using an innate 
immune cell (myeloid) panel. In all cases, the cervicovaginal challenge model of Depo-Provera 
and N-9-treated mice was applied. 
In order to create FRT single cell suspensions, the FRT was dissected (see section 2.7), finely cut, 
and digested in complete DMEM containing 1% HEPES and 20µg/ml Liberase™ TL (Roche), for 1 
hour at 37°C with gentle shaking. Digested tissue was passed through a 70µm cell strainer and 
resuspended in fresh complete DMEM. Single cell suspensions were counted by trypan blue 
exclusion, using a haemocytometer slide and resuspended at a concentration of 1 x 106 cells/mL, 
where 100µL of the suspension was plated in clear 96-well plates (Greiner Bio-One).  
Innate immune cell populations were analysed by multi-colour flow cytometry. The following 
fluorochrome-conjugated antibodies were used: CD45 Alexa Fluor 700 (Biolegend, Clone: 30-
F11), CD11b Brilliant Violet (BV) 421™ (Biolegend, Clone: M1/70), SigLecF PE (Biolegend, Clone: 
S17007L), Gr-1 (Ly-6G+Ly-6C) APC Cy7 (eBioscience, Clone: RB6-8C5), F4/80 BV605 (Biolegend, 
Clone: BM8). Cells were stained in staining buffer (0.5% BSA, 2mM EDTA in 1 X PBS) for 20 
minutes at 4°C (dark), washed and resuspended in staining buffer for acquisition using the BD 
LSR Fortessa. Data was analysed using FlowJo software (V10). Innate immune cell populations 
were identified as CD45+CD11b+/SigLecF+/SSChigh (eosinophils), CD45+CD11b+/Gr-1high 
(neutrophils), CD45+CD11b+/Gr-1intermediate (monocytes) and CD45+CD11b+/F4/80+ (macrophages) 
(Figure 2.2). Uptake of internalized AF488-labelled virions by immune cells were defined as 





Figure 2.2: HPV/SP-A ex vivo infection. Innate immune cell gating strategy. 6 to 10 week-old female wildtype 
C57BL/6 mice were treated with Depo-Provera (s.c.) for 4 days, and then pre-treated with N-9 for 6 hours. 
Thereafter, mice were killed and the FRTs were dissected for the preparation of single cell suspensions. Cells were 
infected with AF488-labelled HPV16-PsVs that had been pre-incubated with BSA (control) or SP-A in a ratio of 1:10 
(w/w) for 1 hour at room temperature. At various time points, cells were stained to visualise and gate the following 
innate immune cell populations by flow cytometry: eosinophils (CD11b+/SiglecF+/SSChigh), neutrophils (CD11b+/Gr-
1high), inflammatory monocytes (CD11b+/Gr-1intermediate), and macrophages (CD11b+/F4/80+). AF488-labelled HPV16-
PsVs uptake/co-localisation by innate genital cells were gated as AF488+ innate cells, based on FMO (uninfected) 
controls. 
 
Three different approaches were taken with regards to analysing the single cell suspensions. 
These were performed to fine-tune the most accurate procedure and subsequent analysis that 
would reflect biologically relevant changes in innate immune cell populations in the early stages 





2.7.2.1 First approach: in vivo infection 
6 to 10 week-old female wildtype C57BL/6 mice were treated with Depo-Provera (s.c.) for 4 days, 
and then pre-treated with N-9 for 6 hours, as described above. The mice were infected 
intravaginally for 2 hours with 1μg AF488-labelled HPV16-PsVs that had been pre-incubated with 
BSA (control) or SP-A in a ratio of 1:10 (w/w) for 1 hour at room temperature. The mice were 
euthanised and the FRTs dissected and single cell suspensions were produced and analysed by 
flow cytometry as described in section 2.7.2 (Figure 2.3). 
 
Figure 2.3: Flow cytometry analysis of mouse FRT single cell suspensions upon in vivo infection with SP-A pre-
incubated HPV16-PsVs (in vivo approach). N-9-treatment of naïve C57BL/6 female mice followed by infection with 
SP-A/BSA pre-incubated AF488-HPV16-PsVs 6 hours later. This was followed by dissection of the FRT 2 hours p.i. to 
create a single cell suspension with fixing, staining and flow cytometric analysis performed all at once. Protocol 
adapted from (29). 
 
2.7.2.2 Second approach: ex vivo infection with a reverse order time-staggered infection of 
FRT single cell suspensions 
6 to 10 week-old female wildtype C57BL/6 mice were treated with Depo-Provera (s.c.) for 4 days, 
and then pre-treated with N-9 for 6 hours, as described above. The mice were then euthanised 
followed by dissection of the FRTs and production of the single cell suspensions. The single cell 
suspensions were plated as described in section 2.7.2. Infection of the cells was performed for 0 
to 8 hours, and this was done in a time staggered, reverse-ordered fashion (Figure 2.4), where 




for 30 minutes were infected last. In each well, 1μg AF488-labelled HPV16-PsVs that had been 
pre-incubated with BSA (control), or SP-A in a ratio of 1:10 (w/w) for 1 hour at room temperature 
was added. 
 
Figure 2.4: Flow cytometry analysis of mouse FRT single cell suspensions upon ex vivo time-staggered infection 
with SP-A pre-incubated HPV16-PsVs (ex vivo approach I). N-9-treatment of naïve C57BL/6 female mice followed 
by dissection of the FRT to create a single cell suspension for subsequent time-staggered infection of SP-A/BSA pre-
incubated AF488-HPV16-PsVs, with fixing, staining and flow cytometric analysis performed all at once. Protocol 
adapted from (29). 
 
2.7.2.3 Third approach: ex vivo infection with fixing, staining and flow cytometry acquisition 
after each infection 
In order to prepare single cell suspensions for this approach, the FRTs of uninfected mice were 
removed 6 hours post N-9-treatment (Figure 2.5). 1 x 106 cells were plated as described and 
infected at 37°C for 30 minutes to 6 hours with 1µg AF488-conjugated HPV16-PsVs which had 
been pre-incubated with purified human SP-A protein or BSA at a w/w ratio of 1:10 for 1 hour at 
room temperature. All cells were infected at the same time, followed by fixing and staining of the 




   
Figure 2.5: Flow cytometry analysis of mouse FRT single cell suspensions upon ex vivo “all at once” infection with 
SP-A pre-incubated HPV16-PsVs (ex vivo approach II). N-9-treatment of naïve C57BL/6 female mice followed by 
dissection of the FRT to create a single cell suspension for subsequent “all at once” infection of SP-A/BSA pre-
incubated AF488-HPV16-PsVs, with fixing, staining and flow cytometric analysis at different time points: t=0 hours, 
t=2 hours, t=4 hours, t=6 hours. Protocol adapted from (29). 
 
2.7.3 Staining for macrophages in the mouse female reproductive tract 
To visualise macrophages and viral particles by IHC, the FRT was dissected from Depo/N-9 treated 
naïve and AF488-HPV16-PsVs (pre-incubated with BSA or SP-A) infected mice (Figure 2.1). The 
tissue was prepared for cryosectioning 2 hours p.i. (or 6 hours after N9 treatment for naïve mice) 
following standard procedures. Briefly, the genital tract tissue was first placed in 4% 
paraformaldehyde for 1 hour to fix the tissue which was then washed 3 X 10 minutes in sterile 
1X PBS. Following washing steps, the tissue was suspended in a 30% sucrose solution overnight 
at 4°C in order to displace any water from cellular spaces and therefore “cryoprotect” the tissue. 
Remaining sucrose was then removed from the tissue by gently blotting with paper towel, and 
tissue was embedded in Optimal Cutting Temperature (OCT, Sakura Finetec USA) compound in a 
plastic mould (Sakura Finetec USA) and frozen over dry ice. Tissue blocks were stored at -80°C 
until cryosectioning. Tissue sections of 20μm were cut using a Leica CM1850 cryostat. These 




which allowed the tissue to adhere to the slides. Samples were then air-dried overnight, 
protected from light. Slides were stored at 4°C for up to a week or at -80°C long-term, protected 
from light. 
Before any IHC staining, samples were removed from storage and left at room temperature for 
30 minutes. Sections were then immersed in cold methanol and incubated for 10 minutes at -
20°C to fix and permeabilise sections. Sections were then washed 3 times in 1X PBS, 10 minutes 
each. Following washing, sections were incubated in IHC blocking solution (Appendix) for 1 hour 
at room temperature to reduce non-specific staining. To stain for macrophages, sections were 
incubated with a specific antibody against murine macrophage surface protein F4/80 (rat-anti-
mouse F4/80, Thermo Scientific) at a dilution of 1:1000 in IHC blocking solution overnight at 4°C 
in a sealed humidified chamber. Non-specific background signal was controlled for by using a rat 
IgG2B isotype control (Invitrogen) at a dilution of 1:1000 in blocking solution overnight at 4°C in 
a sealed humidified chamber. Sections were then washed 3 times in 1X PBS, 10 minutes each. 
Goat-anti-rat AF555 secondary antibody (Invitrogen) was added to the sections at a 1:500 
dilution in blocking solution for 90 minutes at room temperature. This was followed by washing 
as described above. Sections were then incubated in Hoechst Nuclear Stain (0.5μg/mL in 1X PBS) 
for 10 minutes at room temperature, protected from light. After incubation, slides were washed 
in 1X PBS for 10 minutes. Sections were then mounted with 20mm x 20mm coverslips using 
Mowiol, which contained n-propylgallate for its anti-fade properties. Slides were stored at 4°C 
protected from light until viewing. 
Tissue sections were viewed using a Zeiss LSM880 Airyscan confocal microscope together with 
Zen 2.3 SP1 software (Zeiss). Ten areas in the epithelium were randomly selected for each 
condition, using the Hoechst channel only to eliminate bias. Z-stacks were then taken with the 
Hoechst, AF488 and AF555 channels selected. Z-stack dimensions were then normalised to 18 
optical sections per image stack, and maximum intensity projections were done. The area 
occupied by macrophages (positive for F4/80) in the epithelium was determined by outlining the 
epithelium in each maximum intensity projection and determining the area of the AF555 stain in 
these selected regions (Supplementary Figure 2). This was normalised to the area occupied by 




epithelium was predicted to impact the level of immune response, i.e. the number of 
macrophages that are recruited to the basal epithelium. Normalising was done for each individual 
maximum intensity projection by setting the lower and upper thresholds at 18 and 256 greyscale 
levels, respectively. This was done to remove background signal so that the measured signal for 






Two proteins, rhVim and SP-A have been previously shown by our laboratory to modulate HPV16-
PsVs infection in vitro, and in the case of SP-A, in vivo as well (36, 66). SP-A has been hypothesised 
to modulate HPV16-PsVs infection indirectly by enhancing innate immune cell recognition and 
clearing of HPV16-PsVs in the female reproductive tract (66). RhVim, on the other hand, has been 
hypothesised to modulate HPV16 pseudovirus infection by binding to the HPV16-PsVs and 
preventing binding to cell surface, internalisation, and subsequent infection of epithelial cells 
(36).  
This study aimed to further elucidate the mechanisms with which these two proteins modulate 
HPV16-PsVs infection by means of various in vitro and in vivo experiments. 
 
3.1 Production and evaluation of HPV16-PsVs 
Before any in vitro and in vivo experiments using HPV16-PsVs were performed, the purity and 
infectivity of every new preparation was tested. Firstly, SDS-PAGE followed by silver staining was 
used to assess the purity of the HPV16-PsVs preparations (Figure 3.1A, left panel). A predominant 
L1 band at 55 kDa as well as a less predominant L2 band at 75 kDa were expected in pure 
preparations. For HPV16-PsVs that had been labelled with AF488 the SDS gels were illuminated 
with a 488 nm light source, which resulted in visualisation of the successfully labelled fluorescent 
bands before silver staining (Figure 3.1A, right panel).  
Secondly, the infectivity of HPV16-PsVs preparations was assessed by infecting HeLa cells with 
viral particles that had undergone the treatments detailed in section 2.3.4.2. As expected, pre-
incubation of HPV16-PsVs with the neutralising antibody H16.V5, which is HPV16 type specific, 
completely abolished infection (Figure 3.1B). Treatment with DNase I endonuclease was also 
performed to determine whether the measured luciferase activity was as a result of any un-
encapsidated plasmid. In pure preparations, such as the one depicted in Figure 3.1B, DNAse 




Thirdly, selected pure and highly infectious HPV16-PsVs preparations were visualised by negative 
staining electron microscopy (Figure 3.1C). The pseudoparticles were found to exhibit similar 




Figure 3.1: Quality control tests to assess purity and infectivity of HPV16-PsVs preparations. [A] SDS-PAGE gel 
showing the same representative AFF488-labelled HPV16-PsVs preparation, visualised by fluorescence (left gel) 
followed by silver staining (right gel). A thick band corresponding to the L1 protein (55 kDa) as well as a thin L2 band 
(75 kDa) were seen in pure preparations. [B] HeLa cells were infected with HPV16-PsVs under various conditions 
(see sections 2.3.4.2) where luminescence was measured 24 hours p.i. Relative luciferase activity (R.L.U) represents 
luminescence (arbitrary units), and values are presented as x-fold change relative to HPV16-PsVs only, which was 
set as 1. [C] Structural analysis of a representative pure and highly infectious HPV16-PsVs preparation was performed 
by negative staining transmission electron microscopy. 
 
3.2 Surfactant Protein A impairs HPV16-PsVs infection via innate immune cell activation 
3.2.1 The presence of SP-A increases macrophage recruitment to the basal epithelium in the 
genital tract of C57BL/6 mice  
As outlined in section 1.2.4 and Figure 1.4, previous work has shown that pre-incubation of 
HPV16-PsVs with purified SP-A protein led to a substantial increase of viral uptake into RAW264.7 
murine macrophages (66). Therefore, in vivo experiments were performed to validate that SP-A 
enhances HPV16-PsVs recognition by immune cells, thereby affecting overall HPV16-PsVs 




performed using HPV16-PsVs encapsidating the Gaussia luciferase reporter plasmid. As shown in 
Figure 3.2A, pre-incubation of HPV16-PsVs with purified SP-A at a 1:10 (w/w) ratio decreased the 
level of infection over time compared to particles pre-incubated with BSA control, with significant 
reduction seen 72 hours post infection.  
Thereafter, macrophage recruitment experiments by means of IHC and confocal imaging were 
performed to determine whether the observed reduction in infection was due to SP-A mediated 
changes in the overall number of macrophages in the epithelium of the mouse FRT. As innate 
immune cells, macrophages are expected to be involved in the very early responses to infection. 
Therefore, genital tract tissues were dissected 2 hours post infection with AF488-labelled HPV16-
PsVs (pre-incubated with SP-A or BSA control as indicated). Figure 3.2B shows a representative 
image taken of the epithelium, which had been stained for macrophages (F4/80) and cell nuclei 
(Hoechst). The basal epithelial layer (outlined in yellow) was visually distinguishable from the rest 
of the genital tract epithelium and was manually outlined to quantify recruitment of 
macrophages for each condition (Supplementary Figure 2).  
Quantification of the area occupied by macrophages (F4/80 staining) in the basal epithelial layer 
(outlined in yellow) of the FRT of 10 randomly selected images per condition showed a significant 
increase in macrophage recruitment to the basal epithelium in the presence of SP-A, when 
compared to the BSA control treated epithelium (Figure 3.2C). The high standard errors as a result 
of the highly variable and biased nature of this type of analysis should be noted. Therefore, 
subsequent unbiased quantitative flow cytometry analyses of FRT cell suspensions were done in 
order to validate the IHC results and to further analyse whether other innate immune cell 
populations recognise HPV16-PsVs in a SP-A dependent manner, thereby contributing to the 





Figure 3.2: SP-A reduces HPV16-PsVs infection in C57BL/6 mice by increasing macrophage recruitment into the 
basal eptihelium. 6 to 10 week-old female wildtype C57BL/6 mice were pre-treated as described in in section 2.7. 
[A] HPV16-PsVs encapsidating the Gaussia luciferase reporter plasmid pGLuc were pre-incubated with a 10-fold 
(w/w) excess of purified SP-A protein (or BSA control) for 1 hour at room temperature, before intravaginal 
inoculation. Genital tracts were washed with 2 x 50µL PBS at 24 hours, 48 hours, and 72 hours post infection, and 
activity of the secreted Gaussia luciferase in the vaginal lavage fluid as a measure for infection was determined. Data 
of three independent experiments are presented relative to infectivity of the BSA control group at 72 hours which 
was set as 100%. Statistical significance was determined using one-way ANOVA and Bonferroni’s multiple 
comparison tests for the individual time points. *= p<0.05. Bars depict mean values, with error bars showing SEM. 
[B] Mice were treated with N-9 for 6 hours as required for HPV challenge (+N-9) or left untreated (-N-9). AF488 
labelled HPV16-PsVs were pre-incubated with 10-fold (w/w) excess of purified SP-A protein (or BSA control) for 1 
hour at room temperature, before intravaginal inoculation (lower panel) or left uninfected (upper panel) followed 
by dissection 2 hours p.i. and subsequent tissue processing (see section 2.7.3 for further details). Representative 
confocal images of epithelial tissue (blue) exposed to fluorescent virions (green) is shown with staining for 
macrophages in red. The basal epithelium is outlined in yellow. [C] Macrophage recruitment to the epithelium in 
response to SP-A coated HPV16-PsVs was quantified and compared to the BSA control group. Statistical significance 




3.2.2 Analysis of murine FRT single cell suspensions for SP-A mediated HPV16-PsVs uptake 
by innate immune cells  
Since bias during the quantification of macrophage recruitment by confocal analysis (Figure 3.2C) 
could not be excluded, flow cytometry analysis of a myeloid cell panel was used as a more 
unbiased approach to determine whether SP-A had any effect on HPV16-PsVs recognition by 
innate immune cell populations in the FRTs of C57BL/6 mice. This analysis was carried out by 
creating single cell suspensions produced from the dissected genital tracts of female C57BL/6 
mice, before or after infection with HPV16-PsVs. The four cell populations analysed were 
eosinophils, neutrophils, monocytes, as well as macrophages. Adaptations of the cervicovaginal 
challenge model described by Roberts et al (29) were performed to create these single cell 
suspensions, where three different infection approaches were performed while using the same 
flow cytometric analysis for all these approaches (see Figure 2.2). The three different approaches, 
their outcomes and technical limitations are described in detail below.  
 
3.2.2.1 In vivo approach: Preparation and FACS analysis of FRT single cell suspension 2 hours 
after HPV16-PsVs infection of female C57BL/6 mice 
Initially, female C57BL/6 mice were infected with AF488-HPV16-PsVs that had been pre-
incubated with either SP-A or BSA, as described in section 2.7. As a negative control, two groups 
received either the SP-A or BSA protein only. Single cell suspensions were generated from the 
infected mice 2 hours p.i., where four innate immune cell types were stained and analysed by 
means of flow cytometry. Analysis parameters focused on the percentage of the total cell 
population for each innate immune cell population as well as the percentage of a particular cell 
population that co-localised with AF488-HPV16-PsVs.  
As shown in Figure 3.3A, no significant SP-A mediated change in any of the innate immune cell 
populations was observed. With regards to a change in viral uptake (co-localisation with AF488-
HPV16-PsVs) in the different cell populations, a decrease in viral uptake in neutrophils was 




There were technical limitations to this in vivo approach that affected the acquisition and analysis 
of the cell populations. There was a long period of time between dissection of the FRTs and fixing 
and staining of the single cell suspensions, which means that the cells were kept alive well after 
the 2-hour infection period. Too many variables could have affected the cells while kept in 
suspension and thus this approach was determined to not be representative of the innate 
immune response at 2 hours p.i. in the FRT. The next approach aimed to provide more control 
on the length of time the cell suspensions were infected with HPV16-PsVs before being fixed, 













Figure 3.3: In vivo approach: SP-A decreases HPV16-PsVs co-localisation with neutrophils, but does not affect 
immune cell numbers, when FRT single cell suspensions were analysed 2 hours p.i. 6 to 10 week-old female 
wildtype C57BL/6 mice were treated with Depo-Provera (s.c.) for 4 days, and then pre-treated with N-9 for 6 hours. 
Mice were then infected with AF488-labelled HPV16-PsVs that had been pre-incubated with BSA (control) or SP-A in 
a ratio of 1:10 (w/w) for 1 hour at room temperature, where control mice received either SP-A or BSA only. The mice 
were killed 2 hours p.i. and the FRTs were dissected for the preparation of single cell suspensions. The cells were 
stained to visualise and gate the following immune cell populations by flow cytometry: eosinophils, neutrophils, 
inflammatory monocytes, and macrophages (staining details in section 2.7.2). [A] Shown is the percentage of the 
indicated immune cell populations upon infection with HPV16-PsVs pre-incubated with BSA (control) or SP-A, and 
the uninfected control mice. [B] Shown is the percentage of AF488-HPV16-PsVs uptake of each immune cell 
population upon pre-incubation of the viral particles with BSA (control) or SP-A, as well as the uninfected mice. Two 




3.2.2.2 Ex vivo approach I: Time-staggered HPV16-PsVs infection of FRT single cell 
suspensions isolated from naïve C57BL/6 mice  
The next approach was to perform an ex vivo infection, where the female C57BL/6 mice were N-
9-treated for 6 hours, followed by dissection of the FRTs. Thereafter, single cell suspensions were 
produced and infected with AF488-HPV16-PsVs (pre-incubated with SP-A or BSA) using a 
staggered (reverse) time course to allow for the fixing, staining and flow cytometric acquisition 
to be done for all conditions at the same time.  
While there was a considerable difference in the number of most of the immune cell populations 
over the course of infection (with eosinophils and neutrophils decreasing, macrophage numbers 
increasing, and monocyte numbers remaining unchanged over time), there was no significant 
difference in the number of the immune cells present after each time point between the SP-A 
pre-incubated treatment and the BSA control (Figure 3.4A). A significant increase could be seen 
in viral uptake by macrophages with the SP-A pre-incubated treatment at 4 hours p.i., when 
comparing to the BSA control (Figure 3.4B). Other than this, no significant differences were seen 
when compared to the BSA control for any of the other innate immune cell populations at the 
other time points. 
This ex vivo approach made it possible to analyse the immune cell populations at different time 
points post infection, however, this approach also had technical limitations. The single cell 
suspensions that were infected for the shortest period were left to incubate in a humidified 
atmosphere containing 5% CO2 at 37°C for as long as 6 hours before being infected and thereafter 
processed for flow cytometry analysis. These cells therefore did not represent fresh immune cells 
and there was the potential for these immune cell populations and their viral uptake to differ 
from those that were left to incubate for a shorter period of time. 
The next approach aimed to address this issue by infecting the cells all at once and processing 






Figure 3.4: Figure 3.4: Ex vivo approach I: Time-staggered infection of FRT single cell suspensions with SP-A pre-
incubated HPV16-PsVs reveals no changes in viral uptake by innate immune cells. 6 to 10 week-old female wildtype 
C57BL/6 mice were treated with Depo-Provera (s.c.) for 4 days, pre-treated with N-9 for 6 hours and killed. 
Thereafter, FRTs were dissected and single cell suspensions prepared which were then infected with AF488-labelled 
HPV16-PsVs that had been pre-incubated with BSA (control) or SP-A in a ratio of 1:10 (w/w) for 1 hour at room 
temperature. The infection was done in a reverse order, time-staggered manner. The cells were stained all at once 
to visualise and gate the following immune cell populations by flow cytometry: eosinophils, neutrophils, 
inflammatory monocytes, and macrophages. [A] Shown is the percentage of the indicated immune cell populations 
over time upon infection with HPV16-PsVs pre-incubated with BSA (control) or SP-A. [B] Shown is the percentage of 
AF488-HPV16-PsVs uptake for each immune cell population over time, upon pre-incubation of the viral particles with 
BSA (control) or SP-A. Two independent experiments were performed, where pooled data from these experiments 
are presented. Significances were calculated by means of two-way ANOVA and Bonferroni’s multiple comparison 
tests for the individual time points. * = p<0.033; ** = p<0.002; *** = p<0.001. Depicted are mean values, with error 




3.2.2.3 Ex vivo approach II: All-at-once HPV16-PsVs infection of FRT single cell suspension 
isolated from naïve C57BL/6 mice 
The third and final approach was to perform an ex vivo infection of naïve mouse FRT single cell 
suspensions with AF488-HPV16-PsVs that had been pre-incubated with either SP-A or the BSA 
control. This approach, however, involved the infection of all the cells at once, followed by fixing, 
staining, and acquisition after each time point. As evident in Figure 3.5B, the percentage of 
eosinophils and neutrophils decreases as infection progresses, while macrophages increase over 
the course of HPV16-PsVs infection. However, the percentage of the indicated innate immune 
cell populations for any of the infection times showed no significant difference when comparing 
the SP-A pre-incubated with the control BSA pre-incubated cells, which is similar to the 
observations of the ex vivo approach II (Figure 3.4A). Importantly, uptake of AF488-conjugated 
HPV16-PsVs significantly increased in the presence of SP-A for all studied innate immune cell 
populations (Figure 3.5C). This is exemplified for the 2-hour time point in Figure 3.5A. This 
approach was the most optimal as it allowed for more control over the length of time of HPV16-
PsVs infection (by performing an ex vivo infection) and  prevented any variability between the 
single cell suspensions caused by varying lengths of time that the cell suspensions were incubated 
for before HPV16-PsVs infection (this was controlled by infecting all the cells at once and 






Figure 3.5: Ex vivo approach II: All-at-once infection of FRT single cell suspensions with SP-A pre-treated HPV16-
PsVs leads to increased viral uptake by selected immune cell populations. 6 to 10 week-old female wildtype 
C57BL/6 mice were treated with Depo-Provera (s.c.) for 4 days, and then pre-treated with N-9 for 6 hours. Mice were 
killed and FRT dissected for the preparation of single cell suspensions. Cells for all time points were infected with 
AF488-labelled HPV16-PsVs that had been pre-incubated with BSA (control) or SP-A in a ratio of 1:10 (w/w) for 1 
hour at room temperature. At the indicated time points, cells were stained to visualise and gate the following 
immune cell populations by flow cytometry: eosinophils, neutrophils, inflammatory monocytes, and macrophages. 
[A] Representative flow gates of AF488-labelled HPV16-PsVs uptake/co-localisation by innate genital cells at the 2-
hour time point are shown. [B] Shown is the percentage of the indicated immune cell populations over time upon 
infection with HPV16-PsVs pre-incubated with BSA (control) or SP-A. [C] Shown is the uptake of HPV16-PsVs with 
the indicated immune cell populations over time dependent on pre-incubation of the viral particles with BSA 
(control) or SP-A. Pooled data of two independent experiments are presented. Significances were calculated by 
means of two-way ANOVA and Bonferroni’s multiple comparison tests for the individual time points. * = p<0.033; 




3.3 Recombinant human vimentin modulates HPV16-PsVs infection by direct competition 
with the viral internalisation complex on epithelial cells 
As shown in Schäfer et al (36) (see section 1.3.5), pre-incubation of HPV16-PsVs with rhVim led 
to a significant decrease in viral uptake and infection of the human keratinocyte cell line NIKS 
(36), suggesting an inhibitory role in the early events of the viral entry process. However, the 
exact mechanisms of rhVim modulation of HPV16-PsVs infection remains unknown. Therefore, 
in vitro experiments were performed to elucidate how rhVim affects the early stages of HPV16-
PsVs infection, that being cell surface binding of the pseudovirions and subsequent 
internalisation. Furthermore, in vivo experiments were performed to validate whether the in 
vitro results can be applied to a biological model. 
 
3.3.1 The formation of vimentin filaments abolishes the modulatory effect of rhVim on 
HPV16-PsVs infection  
As vimentin has been shown to form filaments in the presence of NaCl (132), in vitro experiments 
were performed to determine whether globular and filamentous rhVim differ in their ability to  
modulate HPV16-PsVs uptake in NIKS cells. Initially, negatively stained electron microscopic 
images of rhVim under varying concentrations of NaCl were taken to determine the structure of 
the vimentin filaments as well as the concentration range at which these filaments start to form. 
Figure 3.6A shows representative images taken of the rhVim protein, where definitive filaments 
are formed at an NaCl concentration of 50mM, and thicker filaments form at a higher 
concentration of 100mM.  
HPV16-PsVs uptake in the presence of rhVim at these varying NaCl concentrations were then 
assessed by means of FACS assays. The decrease in HPV16-PsVs uptake previously seen for a 1:1 
rhVim:HPV16-PsVs (w:w) pre-incubation with 0mM NaCl (36) was abolished when the pre-
incubation step occurred in the presence of NaCl concentrations 50mM and higher (Figure 3.6B). 
These results show that rhVim decreases HPV16-PsVs infection most effectively in the absence 






Figure 3.6: The formation of filamentous rhVim at NaCl concentrations of 50mM and higher abolishes its 
modulatory effect on HPV16-PsVs internalisation by NIKS cells. [A] Structural analysis of rhVim was performed by 
negative staining transmission electron microscopy. rhVim was pre-incubated with varying NaCl concentrations at 
room temperature for 1 hour prior to staining and imaging. [B] Quantification of viral internalisation was performed 
by flow cytometry of NIKS cells infected with AF488-conjugated HPV16-PsVs pre-incubated with rhVim or the BSA 
control at a 1:1 (w/w) ratio at room temperature in the presence of varying concentrations of NaCl (see section 2.5). 
Experiments were quantified by quadrant analysis of the dot plots and presented as % change relative to the mean 
fluorescence intensity of HPV16-PsVs-infected, BSA pre-incubated cells in the absence of NaCl, which was set as 
100%. Combinatorial analysis of three independent experiments are presented. Significances were calculated by 
means of one-way ANOVA and Tukey post-hoc tests. * indicates statistical significance between uptake of HPV16-







3.3.2 Pre-incubation of HPV16-PsVs with rhVim reduces pseudovirus co-localisation with 
surface HSPGs  
The current model of HPV entry suggests that the virus initially attaches to HSPGs at the cell 
surface, followed by conformational changes and transfer of the virus to an unidentified receptor 
(30).  
To further characterise the step(s) which are modulated by rhVim during the early internalisation 
process, more specifically at HPV/HSPG binding, HPV16-PsVs were pre-incubated with non-
filamentous rhVim and subjected to NIKS cells for co-localisation studies by confocal microscopy. 
In order to perform these co-localisation studies, it was necessary to determine successful 
staining conditions of surface HSPGs of NIKS cells. Figure 3.7A shows clear staining of HSPGs, with 
no background signal detected with the secondary only staining control. Using a 1:1000 dilution 
of the AF647 secondary antibody displayed the optimal staining conditions, and so this dilution 
was used in subsequent experiments. 
Figure 3.7B shows representative confocal images of NIKS cells that had either been uninfected, 
infected with AF488-HPV16-PsVs only, or infected with AF488-HPV16-PsVs that were pre-
incubated with either rhVim or the BSA control. The cells were thereafter stained for HSPGs and 
cell nuclei. As expected, no HPV16-PsVs green signal could be detected for uninfected cells. Many 
HPV16 pseudoparticles (green dots) could be seen in the HPV only and BSA pre-incubated HPV 
treated cells. However, there were fewer HPV16 pseudoparticles detected in the cells treated 
with rhVim pre-incubated AF488-HPV16-PsVs when compared to the HPV only and BSA control 
cells.  
The differences in HPV16-PsVs binding observed in Figure 3.7B, were further quantified and 
statistically assessed by co-localisation analysis. The co-localisation coefficients depicted in Figure 
3.7C is understood as the degree of overlap between the HSPG fluorophore and the HPV16-PsVs 
fluorophore and vice versa, where 0 being no overlap and 1 being complete overlap. The top bar 
graph in Figure 3.7C represents the co-localisation coefficient of the AF647 channel (i.e. the 
amount of HSPGs co-localising with HPV) and the bar graph below represents the co-localisation 




there was a high degree of co-localisation between the HSPGs and just HPV as well as the HPV 
pre-incubated with BSA control. RhVim-coated viral particles showed a significantly lower co-
localisation coefficient with surface-expressed HSPGs compared to control particles. Similarly, 
HSPGs showed less co-localisation with the rhVim coated particles, strengthening the 
observation that rhVim decreases binding of HPV16-PsVs to the surface HSPGs of NIKS cells.  
In order to determine any statistical significance for these observations, the averaged co-
localisation coefficients of fifty cells for each treatment were compared. Although this approach 
did indeed yield significant comparisons between the rhVim pre-incubation and the HPV only 
(and BSA pre-incubation controls), it is important to note the large variation and high standard 
error for each treatment, owing to the biased and highly variable nature of the analysis used in 
confocal microscopy. Similar limitations have been noted under section 3.2.1, where the same 






Figure 3.7: Pre-incubation of HPV16-PsVs with rhVim reduces HPV16-PsVs co-localisation with surface HSPGs of 
NIKS cells. [A] Successful staining for surface HSPGs of NIKS cells, with a 1:500 and a 1:1000 AF647-AffiniPure Donkey 
anti-Mouse IgM secondary antibody dilution, as well as staining with Hoechst nuclear stain. Cells stained with only 
the secondary antibody to assess any background signal and nonspecific binding is also shown. [B] and [C] 
Quantification of HPV16-PsVs binding to HSPGs in NIKS cells infected with Alexa Fluor® 488 (AF488)-conjugated 
HPV16-PsVs was performed by co-localisation analysis via confocal microscopy (procedures described in section 2.5 
and 2.6). Images were taken and analysed using a Zeiss LSM 880 AiryScan Confocal Microscope. [B] Representative 
images of the various treatments are shown, with blue nuclei staining and red HSPG staining. [C] A summary of the 
co-localisation (Manders co-localisation coefficient) analysis as shown in [B] using n=50 randomly chosen images. 
Statistical significance was determined using a Mann-Whitney test. ***= p<0.0001. Bars depict mean values, with 




3.3.3 Removal of surface HSPGs decreases HPV16-PsVs binding and internalisation, and to a 
greater extent with rhVim pre-incubation 
As demonstrated in section 3.3.2, co-localisation of HPV16-PsVs with surface HSPGs is 
significantly reduced upon HPV16-PsVs pre-incubation with rhVim. Co-localisation is, however, 
not completely abolished and therefore it cannot be concluded that the effect of rhVim on 
HPV16-PsVs binding to HSPGs is the sole explanation for a reduction in viral uptake and 
subsequent infection. The next experiment therefore focused on the effect of pseudoparticle 
binding and internalisation in NIKS cells upon removal of surface HSPGs by heparinase I treatment 
prior to infection. Figure 3.8A shows confocal images of NIKS cells that had been incubated with 
heparinase I for various lengths of time, as described in section 2.5. It is evident that a 1-hour 
heparinase I treatment completely removed surface HSPGs, and so moving forward this was used 
in the functional studies. 
As expected, a decrease in both HPV16-PsVs cell surface binding and internalisation was 
observed in cells that had been treated with heparinase I (Figure 3.8B),  since the surface HSPGs 
are known to be the initial attachment point of HPV to target cells (133). Interestingly, pre-
incubation of the viral particles with rhVim significantly further decreased both viral binding and 





Figure 3.8: Removal of surface HSPGs from NIKS cells decreases HPV16-PsVs binding and internalisation, while 
rhVim pre-incubation with HPV16-PsVs decreases HPV16-PsVs binding and internalisation to a greater extent. [A] 
Confocal images proving successful removal of HSPGs in NIKS cells (see sections 2.5 and 2.6 for heparinase I and 
staining procedures). Images were taken and analysed using a Zeiss LSM 880 AiryScan Confocal Microscope. [B] 
Quantification of viral cell surface binding and [C] quantification of viral internalisation was performed by flow 
cytometry of NIKS cells infected with Alexa Fluor® 488 (AF488)-conjugated HPV16-PsVs. Combinatorial analysis of 
three independent experiments are presented. Experiments were quantified by quadrant analysis of the dot plots 
and presented as % change relative to the mean fluorescence intensity of uninfected cells which was set as 0%. 
Significances were calculated by means of one-way ANOVA and Tukey post-hoc tests. * indicates statistical 







3.3.4 Pre-incubation of HPV16-PsVs with non-filamentous rhVim decreases HPV16-PsVs 
infection in C57BL/6 mice 
To confirm the in vitro observations on non-filamentous rhVim’s capability to modulate HPV16-
PsVs infection in vivo, the murine cervicovaginal challenge model (as already described for SP-A 
related experiments, see Figure 2.1) was applied.  
As described in section 2.7, carboxymethyl cellulose (CMC) was used as the delivery vehicle for 
the intravaginal administration of all treatments in female C57BL/6 mice. CMC is a bio-adhesive 
polymer designed to mimic the viscosity of a typical vaginal lubricant gel (29). To eliminate the 
possibility that CMC has any effect on the interaction between rhVim and HPV16-PsVs, in vitro 
internalisation assays in NIKS cells were performed as described in section 2.6.1. Figure 3.9 shows 
no significant difference between CMC pre-incubated HPV16-PsVs internalisation in NIKS cells to 
the respective CMC untreated cells. The inhibitory effect of non-filamentous vimentin is seen in 
the presence and absence of CMC. Therefore, it can be concluded that there are no significant 
effects of CMC on HPV16-PsVs internalisation and all subsequent in vivo experiments could be 
safely carried out in the presence of CMC. 
As outlined in section 2.7.1 and shown in Figure 2.1, 6 to 10 week-old female C57BL/6 mice were 
inoculated intravaginally with HPV16-PsVs encapsidating pGluc that had been pre-incubated with 
rhVim (under filament-forming conditions or not) or BSA for 1 hour at room temperature. This 
was followed by welfare monitoring and collection of vaginal lavage samples at 24 and 72 hours 
p.i., where infection was measured using the Gaussia luciferase reporter gene assay (section 
2.7.1). 
HPV16-PsVs infection, regardless of whether the HPV16-PsVs had been pre-incubated with BSA 
or rhVim, resulted in rather low readings at 24 hours p.i. (Figure 3.10), as already observed in the 
SP-A in vivo infection experiments (see section 3.2.1, Figure 3.2A). However, although not 
statistically significant, a decrease in overall infection in the presence of non-filamentous 
vimentin (i.e. 0mM NaCl) was observed which was not seen in the presence of filamentous 




statistical significance, thereby supporting in vitro observations of the modulatory effect of non-
filamentous rhVim on HPV infection (36).  
 
  
Figure 3.9: Pre-incubation of HPV16-PsVs with CMC does not affect HPV16-PsVs internalisation in NIKS cells. 
Quantification of viral internalisation was performed by flow cytometry of NIKS cells infected with AF488-conjugated 
HPV16-PsVs pre-incubated with rhVim or BSA (pseudovirus:protein = 1:1) for 1 hour at room temperature in the 
presence or absence of 3% CMC. Cells were washed extensively and lifted with trypsin to remove surface-bound 
virions, thereby allowing detection of internalised viral particles. Experiments were quantified by quadrant analysis 
of the dot plots and presented as % change relative to the mean fluorescence intensity of uninfected cells which was 
set as 0%. Combinatorial analysis of three independent experiments are presented. Significances were calculated by 
means of one-way ANOVA and Tukey post-hoc tests. * indicates statistical significance between uptake of HPV16-







Figure 3.10: Pre-incubation of HPV16-PsVs with non-filamentous rhVim decreases HPV16-PsVs infection in 
C57BL/6 mice. HPV16-PsVs encapsidating the Gaussia luciferase reporter plasmid pGLuc were pre-incubated with 
rhVim or BSA (pseudovirus:protein = 1:1) for 1 hour at room temperature, before intravaginal inoculation in the 
presence of CMC of 6 to 10 week-old female wildtype C57BL/B mice (n=6) (29). Genital tracts were washed with 2 x 
50µL PBS at 24 and 72 hours p.i., and activity of the secreted Gaussia luciferase in the vaginal lavage fluid as a 
measure for infection was determined. Data of three independent experiments are presented relative to infectivity 
of the BSA control group at 72 hours which was set as 1. Statistical significance was determined using one-way 
ANOVA and Bonferroni’s multiple comparison tests for the individual time points. *= p<0.05. Bars depict mean 
















Infection with HPV is currently incurable, and co-infection with HIV, particularly in those regions 
of the world with high HIV prevalence like Southern Africa, contribute to the vicious cycle of viral 
acquisition, transmission and disease development. This emphasises the need for highly effective 
and easily accessible therapies with regards to HPV prevention and treatment (49). 
Prophylactic vaccination is considered the most effective control of viral infections. Recently, 
highly efficacious prophylactic vaccines against high grade cervical intraepithelial diseases caused 
by the most prevalent oncogenic HPV types 16 and 18 have been developed (134). However, 
despite the great efforts exerted in HPV vaccination programs, these vaccines do not cover all 
the oncogenic HPV types present in malignant lesions and the extent of cross-protection against 
other oncogenic HPV types, of which there are more than twenty that have been identified, is 
largely unknown. In addition, the vaccines are ineffective for women already infected with high-
risk HPV types (19). Therefore, cervical cancer still represents the fourth most common cancer in 
women worldwide (12). This clearly underscores the need for alternative interventions that 
broadly HPV infection. 
This research focused on two proteins, rhVim and SP-A, which have been shown in previous 
studies to decrease infection, and it is theorised that they do so using very different mechanisms 
(36, 66). Since this was a feasibility study it was limited to the use of HPV16-PsVs, which 
represents the most common high-risk HPV type globally. Both in vitro experiments and an in 
vivo mouse model (29) were applied to characterise the modulatory effects of these two proteins 
on HPV infection. For ease of interpretation, SP-A will be discussed first followed by the 









4.1  The modulatory effect of surfactant protein A on HPV16-PsVs infection 
Innate mucosal immune responses in the female reproductive tract, the first barrier associated 
with clearance of incoming HPV, is still an underexplored field. HPV infects epithelial cells at 
mucosal surfaces during primary infection. Due to the ability of HPV to evade several immune 
mechanisms, infiltration and activation of macrophages and DCs (the most likely antigen 
presenting cells) are usually ineffective, and as a result these viral infections lead to inept humoral 
and cellular immunity (26). Failure to develop effective immune responses results in the virus 
reaching the squamous epithelial cells where it remains concealed from the host immune system. 
The resulting persistent infection increases the likelihood of cancer development (34). 
Therefore, an alternative approach for the prevention of HPV infection is the activation of the 
innate immune response leading to enhanced recognition and elimination of the virus before 
infection of its target cells. For this reason, SP-A, a molecule that has recently been shown to 
reduce HPV16-PsVs infection in vitro and in vivo (Ujma MSc thesis, 66) and has been well 
established as an innate immune molecule capable of clearing a broad range of viral and bacterial 
infections primarily in the lung (67, 71–75), was further explored in this study. These preliminary 
studies as well as the findings in this study have recently been published (82). 
Previous studies in our laboratory have shown increased uptake of HPV16-PsVs by RAW264.7 
macrophages upon pre-incubation of the pseudovirions with SP-A. Furthermore, a substantial 
(but not statistically significant) decrease in HPV16-PsVs infection was seen in vivo (Ujma MSc 
thesis, 66). These observations supported the hypothesis that SP-A may be modulating HPV16 
infection by activation of the innate immune system and recognition of HPV16 by immune cells. 
In order to refine the experimental conditions and to provide more accurate measurements of 
HPV16-PsVs infection in the murine cervicovaginal challenge model, viral particles encapsidating 
the secretable reporter Gaussia luciferase were used in time course experiments in order to 
detect luciferase activity from vaginal lavages daily without sacrificing the animals. The 
preliminary studies made use of the reporter firefly luciferase which gave much lower readings 
when compared to HPV16-PsVs encapsidating the Gaussia reporter gene. Firefly luciferase is not 




order to access the luciferase protein, where this may have resulted in experimental variation 
(66).  
Vaginal lavages of HPV16-PsVs-infected C57BL/6 mice were taken under strict experimental 
conditions to minimise variation: vaginal vaults were rinsed with 2x 50μL sterile 1 X PBS by 
pipetting up and down 3 times and pooling the 2 lavages. This was followed by centrifugation to 
pellet the vaginal mucus. As a result of these strictly consistent experimental conditions, less 
experimental variations and a significant decrease in infection was observed at 72 hours p.i. 
(Figure 3.2A). 
Since it was hypothesised that macrophages were likely to be involved in the SP-A-mediated 
reduction of HPV16-PsVs infection (Ujma MSc thesis, 66), macrophage recruitment was studied 
using IHC and confocal microscopy. It should be noted that for successful infection in the mouse 
model used, intravaginal administration of Nonoxynol-9 (N-9) was done a few hours before 
infection (29). N-9 is an over-the-counter spermicide and has been shown to disrupt animal and 
human vaginal epithelium resulting in undesired proinflammatory responses (135–139). This 
evidence makes it unsurprising that the overall recruitment of macrophages into the FRT due to 
N-9 treatment prior to viral challenge was independent of HPV (Figure 3.2B, upper panel). We 
therefore quantified macrophage recruitment into the basal epithelium by comparing infectious 
conditions of SP-A-coated virions with BSA controls only. A significant increase in the amount of 
macrophages at the site of infection (the basal epithelium) in the presence of SP-A was observed 
(Figure 3.2C).   
To study selected innate immune cell populations for their ability to take up HPV16-PsVs in the 
presence or absence of SP-A in an in vivo context, single cell suspensions prepared from murine 
FRT tissue were analysed by flow cytometry over a time course of six hours. Experimental set up 
and optimisation of this protocol formed a part of this thesis, where the established protocol can 
now be used to study innate immune cell populations upon infection with other pathogens of 
interest. Using optimised conditions, it was found that all assessed populations, i.e. eosinophils, 
neutrophils, monocytes and macrophages, displayed strong SP-A-mediated viral uptake 
compared to control, with neutrophils being the most significant cellular responders to HPV16-




There are seemingly conflicting results between the co-localisation analysis performed in Figure 
3.2C (which suggests an increase in the number of macrophages to the basal epithelial layer of 
the mouse FRT in the presence of SP-A) and the flow cytometric analyses of the single cell 
suspensions derived from mouse FRT shown in Figure 3.5B (suggesting no significant increase in 
the number of macrophages in the presence of SP-A). However, analyses of single cell 
suspensions do not qualitatively distinguish between macrophages located in the basal 
epithelium and the intermediate and upper layers of the epithelium. One could therefore 
speculate that it is indeed not the total number of macrophages in the FRT that changes (as 
observed by flow cytometry) but that migration of the macrophages occur in the presence of SP-
A from the intermediate and superficial layers to the basal epithelial layers (as observed by 
confocal microscopy).  
Based on the murine model used in this study, the data suggests that SP-A mediates opsonisation 
of incoming HPV16-PsVs, increased phagocytosis and killing by innate immune cells with an 
overall effect on dampening the infection (Figure 4.1). Besides enhanced phagocytosis, SP-A has 
been shown to aggregate pathogens thereby hindering their entry into host cells. Although this 
effect was not studied, the inhibitory effect of SP-A is not necessarily dependent on agglutination 
(80), and the data presented here strongly suggests an SP-A-mediated innate immune cell uptake 
of the pseudovirions. Although it has been demonstrated that there is a direct biochemical 
interaction between HPV16-PsVs and SP-A (66), which suggests opsonisation as the contributing 
factor for enhanced phagocytosis, it cannot be ruled out that the sheer presence of SP-A at the 
site of infection contributed to enhanced infiltration of innate immune cells and their rapid 





Figure 4.1: Model of the SP-A-mediated opsonisation of incoming HPV16-PsVs, resulting in increased phagocytosis 
and killing by innate immune cells. [A] HPV16-PsVs infection of the basal epithelium in the absence of SP-A. [B] 
HPV16-PsVs infection of the basal epithelium in the presence of SP-A. Opsonisation of HPV16-PsVs by SP-A results 
in an innate immune response characterised by innate immune cell infiltration of the basal epithelial layers and viral 
uptake. 
 
4.2 The modulatory effect of recombinant human vimentin on HPV16-PsVs infection 
Interaction with host cell surface molecules is one of the early (and crucial) steps leading to 
successful viral infection (140). In the case of HPV, it has been shown that HSPGs are the primary 
attachment factors in epithelial cells (123, 141). Specifically, the major capsid protein L1 binds to 
HSPGs on parts of the basement membrane of the FRT that have become exposed as a result of 
epithelial microabrasions and trauma (e.g. due to sexual intercourse or inflammation) (39). 
Viral internalisation occurs approximately 2 to 4 hours after cell-surface binding (142). It has been 




conformational change of the viral capsid, which exposes the L2 minor capsid protein for 
subsequent furin cleavage (37). Furin cleavage is required for successful HPV infection and it has 
been hypothesised to result in a capsid conformation that is able to interact with a non-HSPG 
cell-surface receptor(s) (36, 40).  
These crucial early steps in HPV infection make targeting viral receptors, or identifying novel 
molecules that prevent receptor engagement by incoming viral particles, promising strategies for 
the control of several viral infections (36, 140). 
Vimentin, a type III IF protein, has been previously shown to modulate HPV16-PsVs infectious 
internalisation (36), independently of prior furin cleavage of the virions. The result was surprising 
as vimentin has been shown to facilitate infection of a number of viruses (108, 113–116, 121, 
143). 
It was hypothesised that binding of either cell surface or soluble recombinant vimentin protein 
with the viral particle interferes with the binding of the cell surface molecules utilised by HPV for 
binding and internalisation, either by concealing portions of the virus that interact with its 
receptor(s) or by causing steric hindrance (36). This study aimed to further characterise the 
precise mechanisms by which artificial supplementation with exogenous rhVim modulates the 
early steps of HPV16-PsVs infection. 
As vimentin has been shown to form a filamentous network in the presence of NaCl (101), in vitro 
experiments were performed to determine whether rhVim in its filamentous form had a different 
effect on HPV16-PsVs infectious internalisation compared to non-filamentous form as used in 
previous experiments (36).  
It is evident that in the absence or at low concentrations of NaCl vimentin remains in a globular 
state (Figure 3.6A), while in the presence of 100mM NaCl, rhVim forms a distinct filamentous 
network. Theses experimental conditions were used in further validation studies. 
HPV16-PsVs internalisation by NIKS cells revealed that the decrease in infectious internalisation 
previously reported for rhVim coated viral particles in the absence of NaCl (36) was abolished 
when the rhVim was in its filamentous form (Figure 3.6B). One could speculate that rhVim in its 




interaction of host cell-surface molecules. Another explanation could be that the formation of 
filaments may “hide” a majority of the HPV binding sites on vimentin which results in vimentin 
losing its ability to efficiently interact with HPV. Formation of filaments may even result in steric 
hindrance which could minimise the HPV-vimentin interaction points. Currently, by using 
cryogenic electron microscopy techniques, these precise regions of binding are being elucidated. 
Since only globular vimentin was found to be capable of modulating HPV16-PsVs, all subsequent 
studies were performed in the absence of NaCl. 
As HSPGs are used by HPVs for successful binding and internalisation in epithelial cells, it was 
investigated whether rhVim had any effect on HPV binding to HSPGs. By quantifying the co-
localisation of Alexa Fluor 488-labelled HPV16-PsVs to stained surface HSPGs of NIKS cells, it was 
deduced that rhVim coated HPV16-PsVs resulted in less HSPG co-localisation than the HPV only 
and BSA controls (Figure 3.7B and 3.7C).  
As HPV-HSPG co-localisation still occurred to a certain degree in the presence of rhVim, it could 
not be ruled out that it was solely HSPG binding which rhVim interferes with. HPV is believed to 
interact with a number of cell surface molecules (including the still unknown entry receptor 
(complex)) subsequent to the initial HSPG attachment; therefore, binding and internalisation by 
means of FACS assays were performed subsequent to removal of surface HSPGs by heparinase I 
treatment.  
Binding of HPV16-PsVs to the cell surface of NIKS cells decreased as expected upon removal of 
HSPGs (Figure 3.8B). Although it has been suggested that HSPG binding is critical for successful 
HPV infection, these results do not show a complete reduction in infection upon heparinase I 
treatment. Similar results were seen in a study done by Culp et al., where heparinase I treatment 
in HaCaT cells (a comparable human keratinocyte cell line to NIKS) also did not demonstrate a 
complete reduction in HPV11 infection (32). The same paper demonstrated that HaCaT cells 
secrete a yet unidentified extracellular matrix (ECM) absorption receptor which could absorb HPV 
particles and lead to its internalisation by adherent cells (32). This mode of internalisation in 
keratinocytes was independent of the HSPG internalisation pathway and could be an explanation 




Regardless of the extent of heparinase I treatment on viral binding, cell-surface binding of HPV16-
PsVs to NIKS cells decreased to an even greater extent when pre-coated with rhVim (Figure 3.8B). 
Similar trends were noted for viral internalisation (Figure 3.8C). The further decrease in both 
binding and internalisation in cells that were both heparinase I treated and then incubated with 
rhVim-coated HPV16-PsVs suggests that rhVim may be affecting viral particle binding to HSPGs 
as well as engagement with other unknown cell-surface binding molecules used by HPV in the 
early stages of infection.  
To provide biological relevance to rhVim’s modulation of HPV16-PsVs infection, in vivo studies as 
already described for the SP-A studies were performed.  
Pre-incubation of HPV16-PsVs with rhVim led to a substantial decrease in infection when 
compared to the BSA control in mice (Figure 3.9B). This decrease in infection was observed 72 
hours p.i., as the Gaussia luciferase readings for all the vaginal lavages at 24 hours p.i. were too 
low to quantify noticeable differences between the treatments. Due to time constraints, these 
results were derived from a single experiment and repeats will need to be performed in order to 
validate these observations. 
Taken together, this study shed light on the mechanisms by which rhVim modulates HPV16-PsVs 
infectious internalisation. The data from this study suggests that non-filamentous rhVim, and not 
filamentous rhVim, modulates infectious internalisation of HPV16-PsVs in vitro at at least two 
steps, by preventing binding of the viral capsid to surface HSPGs, and by preventing attachment 
and interaction with the still unknown receptor/receptor complex (Figure 4.2). This is most likely 
independent of furin pre-cleavage of the viral capsid as demonstrated by Schäfer et al (36). 







Figure 4.2: Model of rhVim’s modulation of HPV16-PsVs infectious internalisation. [A] Cell-surface events that 
occur at the early stages of HPV entry into cultured cells. Mature HPV16-PsVs composed of both capsid proteins (L1 
in purple and L2 in yellow) initially bind to HSPGs on the cell surface. This results in a conformational change that 
exposes the N-terminus of L2, allowing access to the furin recognition site followed by cleavage of this site. This 
cleavage further exposes L2, resulting in a capsid conformation that is able to interact with a non-HSPG cell-surface 
receptor(s). [B] Coating of HPV16-PsVs with rhVim prevents binding of the HPV16-PsVs to both HSPGs and the 
subsequent unknown receptor(s) used by HPV16 for successful internalisation and infection of cultured cells, where 











5 Conclusion  
In summary, this study assigned a novel role for SP-A and vimentin in the protection against 
HPV16-PsVs infection in the murine FRT. Although these two proteins demonstrate vastly 
different mechanisms, both lead to an overall decrease in HPV16-PsVs infection as shown in a 
murine infection model. 
Both SP-A and vimentin can be artificially supplied exogenously, leading to recognition and 
binding of HPV particles and modulation of infection. Therefore, future research aims to develop 
these molecules into topical microbicides as an alternative and potentially broad-spectrum 
means to current prophylactic HPV vaccination. 
The current research on the supplementation of SP-A as a means of reducing pathogenic 
infections is significantly more advanced than research on supplementation of rhVim, making SP-
A, currently, a more ideal candidate for further studies in our laboratory into broad-spectrum 
therapies for sexually transmitted viral infections. C. Trachomatis and uropathogenic E. coli,  are 
among the pathogens whose infection has been shown to decrease upon SP-A supplementation 
in vivo and in vitro, respectively (80, 144). Moreover, SP-A inhibits direct HIV infection of CD4 
cells, yet the enhanced DC uptake with SP-A bound HIV in vitro emphasises the need for further 
research (78) particularly in vivo.  
Nevertheless, the identification and characterisation of vimentin as a viral restriction factor 
capable of modulating the early events in HPV16-PsVs infection of epithelial cells, suggests it can 
be a candidate for drug development. Therefore, both SP-A and rhVim may potentially be 
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Composition of solutions used 
Complete medium (DMEM): Dulbecco’s Modified Eagle Medium (DMEM), 10% foetal calf serum 
(FCS) (Biochrom), Penicillin (100U/mL) and Streptomycin (100mg/mL). 
F-medium: 3 vol Ham’s F 12 medium, 1 vol DMEM, 5% FCS, Penicillin (100U/mL), Streptomycin 
(100mg/mL), 0.4μg/mL hydrocortisone, 5μg/mL insulin, 8.4ng/mL cholera toxin, 10ng/mL 
epidermal growth factor (EGF), 24μg/mL adenine. 
Trypan Blue: 0.4% trypan blue in 1 X PBS. 
5X HSB buffer: 125mM HEPES; 2.5M NaCl; 0.1% Brij58; 5mM MgCl2; 500μM EDTA; 2.5% ethanol; 
filter sterilised. 
Light CsCl: 54g CsCl in 200 mL 1xHSB buffer, filter sterilised. 
Heavy CsCl: 77.6g CsCl in 200 mL 1xHSB buffer, filter sterilised. 
KCl isotonic buffer: 20mM Tris, 100mM NaCl, 1.5mM CaCl2, pH 7.0 
FACS wash: 0.5% BSA in 1 X PBS. 
FACS fix: 1% (v/v) formaldehyde in FACS wash. 















Supplementary Figure  1: Flow cytometry analysis of NIKS cell populations, following infection with AF488-HPV16-
PsVs. [A] Shows a representation of the viable cell population using a dot plot of FSC versus SSC representative dot 
plots of fluorescence in the FL1 channel plotted against side scatter for an internalisation assay. [B] Shows the gating 
strategy using the dot plot showing forward scatter (FSC) versus side scatter (SSC) of the negative control using the 




Supplementary Figure 2: Outlining of the basal epithelium of female C57BL/6 mice genital tracts for quantification 
of macrophage recruitment. The area of F4/80 staining in the basal layer of the epithelium of 10 randomly chosen 
images was quantified by setting the lower and upper thresholds at 18 and 256, respectively, to remove any 
background signal.  
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